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Bone defects and fracture non-unions remain a substantial challenge for clinicians 
due to a high occurrence of delayed union or non-union requiring surgical intervention.  
The current grafting procedures used to treat these injuries have many limitations and 
further long-term complications associated with them.  This has resulted in research 
efforts to identify graft substitution therapies that are able to repair and replace tissue 
function.  Many of these tissue engineered products include the use of growth factors to 
induce cell differentiation, migration, proliferation, and/or matrix production.  However, 
current growth factor delivery methods are limited by poor retention of growth factors 
upon implantation resulting in low bioactivity.  These limiting factors lead to the use of 
high doses and frequent injections, putting the patients at risk for adverse effects.  
The goal of this work was to develop and evaluate the efficacy of BMP-2 delivery 
systems to improve bone regeneration.  We examined two approaches for delivery of 
BMP-2 in this work.  First, we evaluated the use of a self-assembling lipid microtube 
system for the sustained delivery of BMP-2.  We determined that sustained delivery of 
BMP-2 from the lipid microtube system was able to enhance osteogenic differentiation 
compared to empty microtubes, however did not demonstrate a significant advantage 
compared to a bolus BMP-2 dose in vitro.  Second, we developed and assessed the 
functionality of an affinity-based system to sequester BMP-2 at the implant site and 
retain bioactivity by incorporating heparin within a collagen matrix.  Incorporation of 
heparin in the collagen matrix improved BMP-2 retention and bioactivity, thus enhancing 
cell-mediated mineralized matrix deposition in vitro.  Lastly, the affinity-based BMP-2 
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delivery system was evaluated in a challenging in vivo bone repair model.  Delivery of 
pre-bound BMP-2 and heparin in a collagen matrix resulted in new bone formation with 
mechanical properties not significantly different to those of intact bone.  Whereas 
delivery of BMP-2 in collagen or collagen/heparin matrices had similar volumes of 
regenerated mineralized tissue but resulted in mechanical properties significantly less 
than intact bone properties. 
The work presented in this thesis aimed to address parameters currently 
preventing optimal performance of protein therapies including stability, duration of 
exposure, and localization at the treatment site.  We were able to demonstrate that 
sustained delivery of BMP-2 from lipid microtubes was able to induce osteogenic 
differentiation, although this sustained delivery approach was not significantly 
advantageous over a bolus dose.  Additionally, we demonstrated that the affinity-based 
system was able to improve BMP-2 retention within the scaffold and in vitro activity.  
However, in vivo implantation of this system demonstrated that only delivery of pre-
complexed BMP-2 and heparin resulted in regeneration of bone with mechanical 
properties not significantly different from intact bone.  These results indicate that 
delivery of BMP-2 and heparin may be an advantageous strategy for clinically 











Bone defects and fracture non-unions remain a substantial challenge for 
clinicians.  Millions of fractures occur each year in the U.S. and 5-10% result in delayed 
union or non-union requiring some type of surgical intervention [1, 2].  Grafting 
procedures are presently the most common treatment used to restore function to damaged 
or degenerated tissue.  These procedures, however, are largely limited by the availability 
of graft material and have resulted in high rates of failure, donor site morbidity, and/or 
disease transmission [1, 3-5].  Nearly 25% of the graft patients experience re-fracture 
and/or continued pain at the donor site, often due to poor mechanical and/or biological 
environments during the repair process [1, 6, 7].  Consequently, there is an immense need 
for new tissue engineering strategies, which aim to restore, maintain, or remodel 
damaged or degenerated skeletal tissues [4, 8-10].  
The success of tissue engineering therapies depends largely on the interaction and 
synergy of the scaffolds, cells, and/or growth factors used to restore and remodel the 
damaged tissue [11].  Few tissue engineering products have gained FDA approval due to 
complex designs, poor control groups for clinical studies, and high costs [12-14].  Thus, 
research has focused on determining methods to more effectively deliver cells, growth 
factors, and other bioactive agents.  
One aspect of tissue-engineered strategies includes the delivery of growth factors 
to induce cell differentiation, migration, proliferation, and/or matrix production.  Growth 
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factor therapies have demonstrated serious potential for tissue engineering because of 
their highly specific activity and ability to induce a variety of cell functions vital to tissue 
repair.  However, current protein therapies are largely limited by protein stability and 
localization at the treatment site, resulting in the use of high doses, and often requiring 
frequent administrations.  To address these limitations, delivery systems that are able to 
maintain protein stability as well as optimally control the rate and location of growth 
factor release to sustain a therapeutic concentration are being investigated.  Existing 
growth factor delivery systems include lipid-based and polymeric encapsulation vehicles, 
matrix carriers, and affinity-based systems.  
Bone morphogenetic proteins (BMPs) have been used in combination with 
various carrier materials, such as collagen and demineralized bone matrix (DBM), for 
bone tissue engineering approaches [6, 15-17].  Presently, collagen is the only FDA 
approved carrier for BMP-2; however, research has shown that BMP-2 has low affinity 
for collagen, leading to rapid diffusion from the construct and a significant decrease in 
the local BMP-2 concentration [15, 18].  Furthermore, soluble or free BMP-2 quickly 
loses bioactivity due to proteolytic degradation and denaturing caused by physiologic 
conditions (i.e. pH, temperature, salt concentration).  Therefore, recent efforts have 
focused on either encapsulating the BMP molecule to protect it from degradation or 
enhancing the binding affinity of BMPs to the carrier material [17, 19-22].  The overall 
objective of this work was to develop and evaluate the efficacy of BMP-2 delivery 
systems to improve bone regeneration.  This objective will be addressed by employing 
two delivery approaches including a lipid-based microtube vehicle for the sustained 
delivery of BMP-2 and a heparinized collagen matrix for BMP-2 retention.  The central 
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hypothesis for this work is that the controlled delivery of BMP-2 will enhance osteogenic 
differentiation in vitro and bone regeneration in vivo. 
1.2 Specific Aims 
The central hypothesis will be tested through the following three specific aims: 
I. Validate lipid microtubes as a sustained delivery system for BMP-2 through in 
vitro bioassays. 
Sustained delivery systems have been developed for the use of various growth 
factors in tissue engineering applications in order to overcome difficulties associated 
with the short half-life of proteins.  However, many of these systems continue to have 
limitations associated with low loading efficiencies and minimal biological activity 
after release.  In order to address these issues, delivery systems with predictable 
release kinetics and loading efficiencies are being developed.  The work in this thesis 
evaluates the use of such a system for the delivery of BMP-2.   
The hypothesis is that encapsulation of BMP-2 in lipid microtubes will provide 
sustained release of BMP-2, thereby maintaining a consistent concentration of BMP-
2, while also protecting the growth factor from degradation, resulting in increased 
mineralization.  The results of Specific Aim I are discussed in Chapter 3. 
II. Evaluate heparin as a BMP-2 binding matrix component in an affinity-based 
delivery system using in vitro bioassays. 
A major limitation of clinical BMP-2 treatments is the rapid diffusion from the 
implant site, causing a significant decrease in local concentration, as well as rapid 
loss of bioactivity in the soluble form.  Various affinity-based delivery systems have 
been developed to sequester and protect the structure of growth factors.  Recently, 
heparin-based systems have been developed to exploit the inherent binding properties 
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with BMP-2.  This work evaluates the incorporation of heparin in a collagen matrix 
system to improve BMP-2 retention and bioactivity.   
The hypothesis is that heparin will significantly enhance BMP-2 retention within 
the collagen matrix and subsequently increase osteogenic differentiation of progenitor 
cells. The results of Specific Aim II are discussed in Chapter 4. 
III. Evaluate the capability of a BMP-2 controlled delivery system to induce bone 
formation in an in vivo critically-sized defect model. 
BMPs were originally identified as molecules that could induce ectopic bone 
formation when implanted in subcutaneous or intramuscular sites, classifying them as 
osteoinductive proteins.  Thus, the in vivo rodent subcutaneous or intramuscular 
ectopic implantation assay has been established as the standard model to demonstrate 
BMP-2 activity in initiating and maintaining the bone formation cascade.   However, 
the ectopic assay does not provide a clinically relevant in vivo model for fracture 
healing.  A challenging segmental defect model will be utilized in this study to assess 
the performance of a BMP-2 controlled delivery system for fracture healing.   
 The hypothesis is that controlled delivery of BMP-2 will enhance bone formation 
in vivo.  The results of Specific Aim III are discussed in Chapter 5. 
1.3 Significance 
Recent advances in biotechnology have led to increased availability of protein 
therapeutics for tissue engineering applications.  These treatments are expected to 
enhance and accelerate tissue regeneration.  However, current protein, or growth factor, 
therapies are limited by poor stability and rapid transport away from the treatment site, 
resulting in the need for controlled delivery approaches.  This work is innovative because 
it examined the use of two delivery systems in efforts to improve BMP-2 mediated 
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mineralization.  First, self-assembling lipid microtubes were used for the sustained 
delivery of an osteogenic growth factor, which did not involve the use organic solvents 
during fabrication and encapsulation processes.  Additionally, we examined the use of an 
affinity-based system to sequester BMP-2 at the implant site and retain the protein 
structure by utilizing the intrinsic binding properties of heparin and BMP-2 without 
covalently linking molecules to the carrier.  Currently, sustained release of growth factors 
is achieved by incorporating the protein into a degradable polymeric vehicle [23-25].  
However, the fabrication of these polymer vehicles often involves the use of organic 
solvents and harsh processes that may denature and deactivate the protein.  Affinity-
based systems have previously been achieved by covalently-linking molecules or growth 
factors to the carrier material [20, 26-28].  While these approaches have shown promise, 
the biochemical processes used can possibly change the structure and binding properties 
of growth factor binding molecules as well as the bioactivity of growth factors [29].  The 
systems investigated in this work are expected to enable BMP-2 to efficiently and 
adequately perform the intended osteoinductive biological effects, in order to reduce 
adverse effects and improve efficacy of BMP-2 therapies. 
This work is significant because it examines delivery methods to help improve the 
efficacy of growth factor treatments, which may lead to the use of lower, safer doses.   
This project is expected to have the following outcomes: (1) lipid microtubes will 
maintain a sustained dose of an osteoinductive growth factor, (2) a heparinized matrix 
will enhance retention and bioactivity of an osteoinductive heparin-binding growth 
factor, and (3) the delivery of heparin and an osteoinductive heparin-binding growth 





2.1 Bone Structure and Function 
 Bone is a metabolically active, dynamic tissue that is constantly being renewed 
and remodeled.  Apart from being the structural scaffold of the body, bone also has a 
large role in hematopoiesis (development of blood cells), maintaining mineral ion 
homeostasis, and protecting tissues and organs (i.e. lungs, heart, and brain).  Bone 
remodeling and regeneration work cooperatively to maintain these physiological needs 
[4].  Renewal and adaptation of bone tissue occurs on four different surfaces in most 
mammals: periosteal, endocortical, trabecular, and Haversian (intracortical) [30].  These 
surfaces differ greatly in their surface area-to-volume ratios, which is largely dependent 
on the mechanical requirements of those surfaces. 
 Bone formation and the subsequent modeling or remodeling act cooperatively to 
define the proper skeletal geometry, maintain mineral ion concentrations, and repair 
damaged bone.  These actions are regulated and carried out by osteoblasts and 
osteoclasts. Bone modeling usually only occurs during developmental phases in children, 
and reduces to an insignificant level after skeletal maturity is achieved.  This modeling 
process consists of resorption by osteoclasts or formation by osteoblasts, but not both at 
the same location [30].  Bone remodeling includes both resorption and formation at a 
location by groups of cells from multiple sources called the basic multicellular unit 
(BMU).  This remodeling process has a primary role in maintaining calcium homeostasis 
in the body [30, 31].  When calcium levels are low, osteoclast activity is stimulated by 
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parthyroid hormone to release minerals from the bone matrix.  When calcium levels are 
above normal, osteoclast activity is inhibited by calcitonin secreted from the thyroid 
gland.  These regulatory activities are constantly occurring in both immature and adult 
bones to maintain proper structure and function.  Many metabolic bone diseases are 
attributed to interruptions in the normal BMU function (i.e. osteoporosis, osteoarthritis) 
[30, 32].   
Bone formation occurs either by intramembranous ossification or endochondral 
ossification.  Intramembranous ossification occurs when ostoeblasts differentiate within a 
mesenchymal or fibrous connective tissue, such as in the deep layers of the dermis, 
without formation of cartilaginous intermediates [33].  Osteoblasts cluster within the 
tissue and begin to secrete organic matrix, which then becomes mineralized.   Flat bones, 
such as the mandible and clavicle, normally form by intramembranous ossification.  
Intramembranous bones may also form in abnormal locations in response to stresses or 
signals, resulting in heterotopic or ectopic bones.  Endochondral ossification occurs when 
cartilaginous matrix is mineralized into bone tissue [33-35].  This process begins with 
undifferentiated progenitor cells differentiating into chondrocytes and subsequently 
secreting cartilaginous matrix.  After the matrix calcifies and the chondrocytes within the 
matrix to undergo hypertrophy, osteoprogenitor cells and blood vessels invade the matrix.  
The progenitor cells then differentiate into osteoblasts and bone formation occurs on the 
calcified cartilage matrix.  Most long bones, like the femur and tibia, are formed and 
repaired by endochondral ossification. 
Mechanical stimuli have effects on bone remodeling, and research has that bone 
will adapt to the loads experienced [30, 36].  At the extremes, overuse and disuse both 
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result in stimulation of unbalanced bone turnover.  In the case of disuse, or lack of use, 
bone resorption dominates bone formation on endocortical, cortical, and trabecular 
surfaces, resulting in rapid bone loss.  This effect is often observed in astronauts and 
chronically ill patients on bed rest for extended periods of time.  Overuse causes damage 
to the bone, which then stimulates bone remodeling to repair the microdamage.  
However, if damage accumulates faster than repair can occur, the microcracks can 
propagate and result in a fracture [37].  
The major functions of bone are carried out by osteoblasts and osteoclasts.  
Osteoblasts are cells of mesenchymal lineage and secrete unmineralized bone matrix, 
called osteoid, which then mineralize to yield mature bone.  Mesenchymal stem cells 
found in the marrow and periosteum are induced to differentiate into osteoblasts by a 
complex interaction of growth factors and transcription factors, such as Runx2/Cbfa1 and 
Msx2 [30, 38, 39].  Once these cells are committed to the osteoblastic lineage and 
become mature osteoblasts, they begin to express matrix proteins such as bone 
sialoprotein (Bsp), collagen type I, osteocalcin (OCN), and alkaline phosphatase (ALP).  
Some osteoblastic cells do not fully mature and instead begin to form long cytoplasmic 
processes through the osteoid and become osteocytes.  Mature osteoblastic-formed tissue 
is maintained by osteocytes and bone-lining cells.    
Osteoclasts are cells of hematopoetic cell lineage and resorb bone via secretion of 
acid and proteases.  Osteoclastogenesis includes the stimulation of a hematopoetic stem 
cell to form mononuclear preosteoclast cells.  These committed preosteoclast cells then 
enter the blood stream and travel to the site that is to be resorbed.  The mononuclear 
preosteoclasts fuse together for form multinucleated osteoclasts.  This fusion requires the 
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presence of macrophage colony stimulating factor (M-CSF) and receptor activator of 
nuclear factor κB (RANK-L) [30].  Mature osteoclasts resorb bone by secreting H+ ions 
to solubilize the mineral component and subsequently release proteases to degrade the 
organic matrix.   
Mechanical stimuli have an affect on bone cell behavior via mechanotransduction, 
which involves ion channels, focal adhesions, and G-protein coupled receptors.  
Osteocytes and bone lining cells play important roles in communicating these 
mechanotransduction signals through the bone.  Osteocytes have been shown to have an 
indirect response to mechanical stimuli, usually in the form of fluid flow caused by the 
mechanical loading event [30, 40].  This mechanical stimulation causes the osteocytes to 
release prostaglandins to signal cell responses.  Osteoblasts are also involved in 
mechanotransduction, releasing prostaglandins and growth factors upon mechanical 
stimulation.   
Bone extracellular matrix is very dense and heterogenous, largely composed of 
collagen and hydroxyapatite.  Hydroxyapatite crystals are formed when calcium 
phosphate (Ca(PO4)2) interacts with calcium hydroxide (Ca(OH)2), thereby maintaining 
mineral ion homeostasis [31, 41].  These crystals also incorporate other calcium salts, 
such as calcium carbonate, and ions such as sodium, magnesium, and fluoride.  
Hydroxyapatite crystals are very hard, but relatively inflexible and brittle.  Collagen 
fibers, conversely, are strong and flexible and make up approximately 90% of the bone 
ECM [31].  These fibers can tolerate twisting, bending, compression and tension.  The 
collagen fibers provide an organic framework for the formation of hydroxyapatite 
crystals.  During osteogenesis, ascorbic acid and phosphates are in high demand to 
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synthesize collagen type I fibrils and subsequently form hydroxyapatite crystals.  The 
bone matrix also contains proteoglycans and glycoproteins [31, 41].  Fibronectin and 
laminin are two of the main glycoproteins in bone ECM and bind other ECM 
components, such as collagens and proteoglycans.  Matrix composition and structure is 
maintained by matrix metalloproteases (MMP), which cleave matrix proteins.  Bone 
ECM proteins have a major role in regulating growth factor activity by limiting diffusion 
and blocking receptor-binding sites.   
Bone ECM is then organized into woven or lamellar bone.  Woven, or immature, 
bone has randomly arranged collagen bundles.  This random organization causes the 
woven bone to be weaker, but more flexible than lamellar bone.  During the remodeling 
process, woven bone is replaced by lamellar bone.  Lamellar bone has tightly organized, 
parallel sheets of collagen bundles called lamellae.  The lamellae are organized 
concentrically around a canal, which contains blood vessels and nerves, to create an 
osteon or Haversian system [30]. 
On a more global scale, bone has two main structures: compact bone and spongy 
bone.  The matrix compositions of compact and spongy bone are the same, but they differ 
in the three-dimensional organization [30, 42].   Compact bone has a basic functional unit 
called osteon, or the Haversian system.  The osteon consists of osteocytes arranged 
around a Haversian canal that contains blood vessels and run parallel to the surface of the 
bone.  Perforating canals, or the canals of Volkmann, extend nearly perpendicular to the 
tissue surface and deliver blood to osteons deeper within the bone and in the marrow 
cavity.  The periosteum is a layer of connective tissue that covers the surface of the 
compact bone and functions to isolate the bone from surrounding tissues, provide a route 
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for circulatory and nervous supply, and actively participates in bone growth and repair.  
Spongy or trabecular bone is present at the epiphyses of long bones and may extend into 
the marrow cavity, where the bones may experience stress from multiple directions [37, 
43].  The spongy bone has an open structure consisting of struts and plates called 
trabeculae.  This orientation and open structure reduces the weight of the skeleton while 
providing optimal mechanical integrity [30, 37, 43].  The trabeculae are covered by the 
endosteum, which is active in the modeling and remodeling of bone [30].  Nutrients reach 
osteocytes by diffusion along the canaliculi along the surfaces of the trabeculae, and not 
by blood vessels. 
The mechanical properties of bone vary depending on the anatomic function and 
location, age, disease, and the amount of use.  However, the mechanical properties of 
mammalian bone across species are similar [30].  Long bones, such as femurs, are thick-
walled hollow cylinders.  This allows for the long bones to remain strong while 
minimizing the weight.  Much of the strength in long bones is in the periosteum, which 
increases the second moment of inertia and resists against bending or torsional loading 
[30].  Trabecular bone aligns with maximum stresses in bone, however anisotropy greatly 
increases the load-bearing capacity without increasing mass [30, 37, 43].  Collagen fibril 
alignment and cross-linking also greatly influences mechanical strength [43].  
2.2 Fracture Healing 
Bone is one of the few tissues in the body that maintains the ability to regenerate 
in adult life, which is required for fracture healing [44, 45].  The fracture repair process 
must restore the original geometry, biological matrix, and biomechanical properties to the 
damaged bone tissue.  To meet these criteria, fracture healing involves the complex 
 12 
cooperation of angiogenesis and osteogenesis stimulated by a combination of cells, 
cytokines, growth factors, hormones, and ECM components [4]. 
Fracture healing begins with the formation of a large blood clot, or fracture 
hematoma, at the site of fracture to close off the injured vessels [2].  This hematoma 
releases growth factors and cytokines from degranulated platelets and provides a fibrous 
framework at the damaged area for cells to attach and make new bone tissue.  Cells from 
the periosteum migrate to the fracture site to form an external callus.  These periosteal 
cells also rapidly produce BMPs in order to recruit progenitor cells to the site of fracture 
to proliferate rapidly and differentiate [46, 47].  Endogenous expression of BMPs is 
critical to adult bone formation [48].  Cartilage forms at the center of the external callus 
and the chondrocytes produce factors that induce osteogenesis [49, 50].  Blood vessels 
then begin to invade the callus, the cartilage cells hypertrophy, and cells begin to 
differentiate into osteoblasts.  These osteoblasts secrete matrix and gradually replace the 
cartilage with bone.  Osteoclasts and osteoblasts then remodel the region to integrate the 
newly formed bone with the surrounding tissue. 
Fracture healing requires that vascular supply be adequately repaired in order to 
form the fracture callus and supply nutrients to the cells within the fracture callus [2].  
This interdependency of angiogenesis, the regeneration of blood vessels, and bone repair 
has been recognized for many years and established in many studies [2, 51-53].  Vascular 
endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) have been 
shown to have synergistic effects during fracture healing [54, 55].  Inhibition of 
angiogenesis significantly suppresses fracture healing in animal models [53].  Inhibition 
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of VEGF was shown to disrupt bone healing in femoral fractures and cortical bone 
defects by Street, et al. in both murine and rabbit fracture repair models [51].     
Angiogenesis is a complex process regulated by multiple pathways.  VEGF-
related molecules mediate neo-angiogenesis and are mitogens specific for endothelial 
cells [56-58].  VEGF-stimulated angiogenesis involves migration of endothelial cells, 
inhibition of endothelial cell apoptosis, and up-regulation of endothelial-derived 
vasoactive molecules (i.e. tissue plasminogen activator and nitric oxide). Angiopoietin 
molecules regulate the formation of larger vessels and the development of co-lateral 
branches from existing vessels [52].  These angiogenic factors promote endothelial cell 
survival and vessel integrity.  VEGF promotes new vessel formation by remodeling 
capillary basal lamina and stimulating endothelial cell migration and sprouting.  
However, the delivery of VEGF alone is not sufficient to complete angiogenesis and 
requires the delivery of other angiogenic factors to complete the process [59].  Inhibitors 
of angiogenesis, such as TNP-470 and thalidomide, also regulate blood vessel formation 
[53, 60].  Some of these negative regulators, or antiangiogenic factors, have been used in 
clinical trials to inhibit tumor growth and atherosclerosis [60].   
 Mechanical stimulation has been shown to be beneficial during fracture healing 
by regulating gene expression and differentiation of the surrounding tissue [36, 61, 62].  
Several groups have demonstrated that displacement applied to a fracture results in the 
formation of a larger cartilaginous callous and earlier bone bridging [61].  A 
mechanically stable healing environment decreases the amount of cartilage formed at the 
fracture site, indicating that bone formation would occur primarily by intramembranous 
ossification in a stable fracture site [61].  However, when there is excessive motion at the 
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defect site the bone forms by endochondral ossification and the instability prolongs the 
cartilaginous phase [63].   
 Fracture repair is a highly regulated and coordinated activity, down to the cellular 
and molecular levels.  Major advancements in bone biology have been made in recent 
years, revealing more information of the molecular mechanisms behind bone 
regeneration [39, 45, 64].  This information will be helpful in finding new treatments for 
bone fractures, congenital defects, and degenerative diseases.  During osteogenesis, 
BMP-2 activates Smad signaling and regulation of osteogenic genes (i.e. ALP, type I 
collagen, osteocalcin, and bone sialoprotein).  These genes are also regulated by 
expression of the transcription factor Runx-2.  BMP-2 regulates Runx-2 expression 
through Smad signaling, which is required for the regulation of Osterix (Osx) expression 
[65-67].  This is known as the BMP-2-Smad-Runx2 axis in osteogenesis.  Disruption of 
either BMP-2 or Runx-2 in this signaling cascade will result in a lack of bone formation 
and fracture repair [68, 69]. 
2.3 Bone Fracture and Clinical Intervention 
There are many types of bone fractures, with varying clinical treatments.  
Fractures are typically classified based on the site of fracture, nature of the fracture, and 
the external appearance.  These fractures can be a simple transverse fracture that typically 
requires no surgical intervention, or can be as severe as a comminuted fracture, which 
rarely heal spontaneously in patients and require some type of surgical treatment.  
Frequently, bone fractures experience impaired healing, in the form of delayed union or 
nonunion [34, 70].  This impaired healing is often due to inadequate mobilization of the 
fracture, distraction of the fracture by fixation devices, repeated manipulations, periosteal 
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damage during operative procedures, infections, or poor vascular supply [1, 34, 61].  
Such defects can be treated with a graft to promote healing. However, impaired healing is 
not always due to severe fracture conditions.  Diseases such as cancerous tumors in the 
bone (osteosarcoma) and chronic infections of the bone (osteomyelitis) are also very 
challenging for orthopedic treatments [71, 72].   
Burwell showed over 40 years ago that fracture-healing was enhanced when 
cancellous bone grafts were implanted due to the presence of osteoprogenitor cells in the 
graft [73].  Autografts have been the standard treatment for bone fractures because the 
patient will not have a minimal immune response to their own cell source.  However, the 
use of autografts is largely limited by the supply of available graft material.  Typically, 
the graft is taken from the iliac crest of the pelvis, which only provides a small amount of 
material because removal of too much material may result in donor site morbidity, 
leaving the patient in a great amount of pain at both the donor site and at the fracture site.  
The material obtained from this site is also not structurally sound, being made of only 
small bone chips.  Clinical trials have also utilized external stabilization of the graft 
material, often with a titanium chamber, or combining with other matrix components, 
such as calcium sulfate in order to improve the mechanical and biological environment 
[1].  However, these approaches often still result in re-fracture, non-unions, and/or repeat 
surgeries.   
Allografts are also used in the treatment of large fractures.  These grafts are 
obtained from cortical cadaver bone and devitalized to ensure sterility, minimize immune 
response, and prevent disease transmission.  The processed graft is then void of all living 
material and bioactive factors that were originally stored in the bone matrix.  Therefore, 
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the allograft serves mainly as a structural scaffold at the fracture site, and has no 
bioactive component to encourage healing and incorporation of the grafts [4, 74, 75].  
Xie, et al. demonstrated a novel approach of combining structural allografts with 
genetically modified mesenchymal stem cells to improve fracture healing [74].  
Allografts have shown some success in healing fractures, however are much less efficient 
than autografts and still have problems associated with infections, despite the extensive 
screening and decellularization techniques, as well as low osseointegration with host 
tissue [6, 76, 77].  The lower efficiency of allografts is mainly due to the low osteogenic 
activity, caused by the decellurization process, as well as the low porosity, leaving 
minimal space for revascularization and revitalization, leading to slow remodeling of the 
graft.  This results in an accumulation of microdamage and ultimately leads to graft 
failure.   
Tissue engineering may provide alternatives to allografts and autografts by 
restoring, maintaining, and/or improving tissue function [78].  This strategy typically 
includes a matrix or scaffold material, bioactive factors, and/or cells either transplanted or 
recruited to the fracture site.  Some clinical studies have shown improved healing in 
spinal fusions and other osseous defects using tissue engineered constructs [79-81].  
However, tissue engineering products have faced many challenges in becoming clinical 
treatments, including variability in product performance, clinical trial validation, and 
manufacturing scalability [4, 13, 42].  Tissue engineering remains a “development-stage” 
industry with many products failing to gain FDA approval [12, 14].  Therefore, grafting 
procedures remain the standard treatment for many organ and tissue problems, including 
bone fracture repair.  The work presented in this thesis represents one tissue engineering 
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strategy to deliver bioactive factors within a porous polymer scaffold, with the aim to 
promote osseointegration of the scaffold into a bony defect site and enhance functional 
repair of the fracture site.   
Table 2.1 Current and emerging therapeutic strategies for bone regeneration 
AUTOGRAFTING ALLOGRAFTING XENOTRANSPLANTS BIOMATERIALS/DEVICES TISSUE 
ENGINEERING 
Tissue transplanted 
to another area of 
the same patient 
Tissue transplant from 
a matched donor  
Transfer 
cells/tissues/organs from 
animal source to patient 
Replicate tissue function with 
artificial materials 
Restore structure 
and function to 
damaged tissue  
Risks: Infection and 
pain at the donor 





shortages, poor tissue 
remodeling, high rate 
of refracture 
Risks: Tissue rejection 
and infection, zoonotic 
disease transmission 
Risks: Non-physiological 
behavior, material fatigue and 
fracture, toxicity 
Risks: Still a 
developing 









Benefits: Tissue supply 
readily available 
Benefits: Off-the shelf 




2.4 Growth Factor Therapy 
Bone regeneration is regulated by a variety of signals including mechanical 
stimuli, cell-cell interactions, and soluble bioactive factors.  Many proteins are involved 
in this signaling process, making them a potential therapy for various tissue engineering 
applications.  Growth factors are proteins secreted by cells that specifically bind to 
membrane receptors to stimulate or inhibit a cellular function, such as differentiation.  
Multiple studies have shown that administering high concentrations of osteogenic growth 
factors promote fracture unions [33, 47, 82, 83].  The growth factor BMP-2 (bone 
morphogenetic protein-2) was selected for this thesis work to promote and accelerate 
bone tissue regeneration, because of its known osteoinductive capacities.   
BMP-2 is the most widely used growth factor to stimulate osteogenesis [6].  
Marshall Urist was the first to observe the osteoinductive effect of BMPs in 1965 and 
later found a method to extract BMPs from demineralized bone matrix (DBM) [84, 85].  
BMPs increase the synthesis of structural components of ECM, decrease ECM 
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degradation, and increase proliferation.  During fracture healing, BMP-2 expression is 
highest at the early stages to initiate and direct migration of progenitor cells for the 
formation of new bone, which is critical to the proper healing of damaged tissue [33, 64, 
69, 86].  Only BMP-2, -6, and -9 are able to induce and maintain the entire bone 
formation cascade – chemotaxis, proliferation, and differentiation [9, 44, 84, 85].   
Chemotaxis is the guided movement of cells, often mediated by up-regulation of integrins 
β1 and β3, in response to a chemical signal gradient [87, 88].  BMP-2 is endogenously 
expressed in MSCs, which stimulates osteogenic differentiation [89].  However, defects 
in BMP-2 expression may cause autosomal dominant fibrodysplasia ossificans 
progressiva (FOP), myositis ossificans, or osteogenic sarcoma [84].  
BMP-2 is a low molecular weight glycoprotein in the TGF-ß family with a 
disulfide-linked homodimer structure.  Native bone contains approximately 1-2 
micrograms of BMP per kilogram of cortical bone [84, 90].  However, extraction is 
difficult, frequently yielding BMPs with high contamination and unpredictable behavior.  
Due to recombinant protein technology however, BMP-2 is readily available in a highly 
purified form.  Yet, the clinical cost of these recombinant proteins is very high due to the 
limited yield obtained from mammalian Chinese hamster ovary (CHO) cells.  One way to 
increase yield is to produce the proteins in Escheria coli (E. coli).  However, the BMP-2 
produced by E. coli lacks the posttranslational glycosylation sites and folding motifs seen 
in mammalian cell-derived BMP-2, and also has a slightly lower effect on osteogenic 
differentiation [91].    These posttranslational processes can be recreated using optimized 
renaturing procedures, but these processes are often complex and expensive [92].   
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Soluble BMP-2 is secreted from cells in an active form and then behaves in an 
autocrine or paracrine manner by binding the BMP I and II receptors (Ser/Thr kinase 
receptors) [34, 93].  Dimerized BMP-2 binds the receptor complex and the activated 
BMPRII phosphorylates BMPRI, which then recruits and phosphorylates Smads 1, 5, and 
8.  These Smads then associate with Smad 4 and translocate to the nucleus to activate 
transcription [44].  The dimeric conformation of BMP-2 is critical to the bioactivity, but 
is very sensitive to environmental conditions.  Elimination of the disulfide bond between 
dimers renders the molecule inactive [94].  BMP-2 is the most soluble at pH < 5, 
however the solubility at pH > 6 (i.e. physiologic pH = 7.4) is greatly increased in 
solvents such as heparin solutions [95].  Heparin has also been shown to improve BMP-2 
activity by protecting the protein from degradation and blocking antogonist suppression 
(Figure 2.1) [96]. 
Antagonists of BMP-2 include noggin and chordin, which directly bind BMP-2 
and interfere with receptor binding, as well as Smad 6, which inhibits phosphorylation of 
Smads 1, 5, and 8 by BMPRI [93].  Other antagonists, such as fetuin, bind to the 
receptors, inhibiting proper receptor-ligand interactions [93].  Other research has 
suggested that BMP-2 and BMP-4 act as antagonists to each other due to their highly 




Figure 2.1 Mechanisms of heparin effects on BMP-2 activity (Image by Zhao, et al. 
[96]).  Without heparin (left panel), BMP-2 is quickly degraded, suppressed by 
antagonists (i.e. noggin), or internalized after receptor binding.  Heparin helps maintain 
extracellular concentrations of BMP-2 (right panel) by binding to the protein and 
protecting it from degradation and antagonist suppression, as well as keeping the BMP 
receptor continuously activated. 
Research has shown that hMSCs endogenously express and secrete BMP-2, 
resulting in osteogenic differentiation [89].  However, the effects of BMP-2 are 
concentration dependent.  Femtomolar concentrations of BMP-2 influences chemotaxis, 
nanomolar concentrations of BMP-2 influences proliferation, and micromolar 
concentrations of BMP-2 induces differentiation [34, 84, 97].  High doses of BMP-2 (100 
µg/ml in rats), however, have been shown to cause excessive bone formation that spreads 
outside the native shape of the bone [97]. 
The FDA approved the use of rhBMP-2 in Medtronic’s InFUSE™ Bone Graft 
(Medtronic Sofamor Danek, Memphis, TN, USA) for spinal fusion procedures to treat 
degenerative disc disease, and more recently approved for acute, open tibial fractures [98, 
99].  The InFUSE™ Bone Graft delivered with a dose of 1.5 mg/ml BMP-2 in an 
absorbable collagen sponge (ACS) was shown to induce faster fracture healing and 
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reduce the risk of failure, as well as fewer infections and surgical interventions [11, 99].  
Although, collagen is a biocompatible and resorbable carrier material, BMP-2 has a low 
affinity for collagen and has been reported to rapidly clear from the sponge when 
implanted [100-102].  This has caused clinicians to use high doses of BMP-2 in order to 
overcome the diffusion and stability limitations, resulting in extremely high costs and 
reports of adverse effects of the treatment.  The risks initially reported by Medtronic 
included transient increases in BMP antibodies in 5-10% of patients, local edema, and 
accelerated bone resorption [6, 103].  Moreover, in July 2008 the FDA warned surgeons 
that it had received 38 reports in four years of life-threatening complications associated 
with off-label usage of the InFUSE™ device in the cervical spine [103, 104].   Many of 
these complications involved unwanted bone growths near nerves or in areas outside the 
targeted site of treatment leading to severe pain, swelling of the neck and throat, and 
breathing difficulties [104].  Many of these patients required emergency tracheotomies, 
feeding tubes, and repeat surgeries.   
2.5 Growth Factor Delivery Methods 
BMP-2 has been shown to promote fracture unions, however, delivery of BMPs 
alone is minimally effective and not reasonable for wide use clinically due to the 
extremely high doses needed, which may cause cyst-like bone voids [82].  Large, super-
physiologic doses of growth factors are often necessary to overcome their short half-lives 
in vivo because of rapid denaturing of the protein structure by enzymes and other adverse 
conditions in the body (i.e. temperature, pH, ion concentration).  These adverse in vivo 
conditions greatly affect the efficacy, bioavailability, and stability of the growth factor.  
Therefore, optimized drug delivery methods are needed in order to preserve the protein 
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structure in the unfavorable in vivo environment, as well as present the growth factor at 
the appropriate rate, duration, and location of exposure to promote cell responses.  Three 
main approaches have been developed to deliver BMPs including: delivery of DNA 
encoding for BMPs, ex vivo gene therapy or overexpression of BMP genes in cells, and 
delivery of the protein itself in a carrier material [82, 105, 106].  Due to the advances in 
recombinant protein technology and safety concerns with gene therapy, delivery of the 
actual protein has become more widely used [100].   
In order to attain optimal activity, growth factors should to be delivered in a 
manner that will closely relate to the regenerating tissue process of interest [101, 107, 
108].  Thus, there are several important factors considered when designing a growth 
factor delivery system.  First, the delivery method must target the desired cell population 
with minimal diffuse signaling into the surrounding tissue.  Early applications 
administered growth factors via injections, however this approach proved to be 
insufficient due to the short half-lives of growth factors as well as transport away from 
the site of injection/implantation by convective transport (i.e. blood flow, fluid flow due 
to tissue deformation) or diffusion, resulting in effects on at undesired locations [90, 
109].  This has led to the development of new formulations that address the 
pharmacological and therapeutic properties of the growth factor.   
Next, the delivery system must help protect the structure and bioactivity of the 
growth factor.  This has previously been achieved with various growth factors by 
encapsulating the protein [19, 22], thus protecting the structure from proteolytic 
degradation, and also by immobilizing growth factors into an ECM-like matrix to 
sequester the protein [26, 110].  Affinity-based delivery systems utilize unique binding 
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properties of the growth factor and immobilized molecules, to mimic the naturally 
occurring growth factor delivery system in the ECM. Binding of the growth factors with 
immobile molecules slows the rate of diffusion through the surrounding tissue as well as 
maintaining the protein structure.  Molecules such as heparin and antibodies have been 
adsorbed onto or covalently linked to scaffold surfaces to sequester growth factors such 
as bFGF, TGF-ß2, BMP-2 and NGF [17, 20, 111-116].  Recently, chemical alterations 
have progressed to changing the BMP-2 amino acid sequence to improve collagen 
binding, using a known collagen binding domain from the vonWillebrand factor [21].  
The delivery of growth factors in these affinity systems can be controlled by changing the 
overall affinity between the material and the growth factor (i.e. number of binding sites) 
or the rate of degradation of the matrix material.  However, some of these approaches 
often still damage the protein due to the use of harsh solvents and high temperatures 
during the fabrication process.   
Finally, the temporal and spatial release kinetics of the growth factor need to be 
controlled in order to most effectively act on the target cells [3].  These criteria have been 
addressed through various approaches including encapsulation, covalent linking and other 
chemical alterations, or co-delivery with other factors [21, 22, 96, 117].  Controlled 
release is often achieved by encapsulating the growth factor within a polymer to change 
the duration of bioactivity in order to maintain the concentration of growth factor at the 
implant site [22-24].  Release rates of proteins from the delivery vehicle are usually 
controlled by the diffusion properties of the protein and/or the degradation properties of 
the polymer.  Proteins have been encapsulated in nano- or microparticles [22, 24, 25], 
electrospun nanofibers [118, 119], or lipid-based systems [120].  Controlled release can 
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also be achieved through matrix delivery systems (i.e. hydrogels) that have proteins 
uniformly dispersed in a biocompatible polymer carrier and release the protein as the 
matrix degrades [82, 112, 121].  In matrix systems, the release rate is driven by the 
degradation properties of the matrix material and the diffusion properties of the growth 
factor (i.e. concentration, molecular weight) [107].  
In addition to the biochemical properties of the delivery system, the mechanical 
and physical properties (i.e. size, shape) have a role in the efficacy of growth factor 
delivery [122].  Physical properties can influence the interactions between the delivery 
system and the cells (i.e. endocytosis, circulation, targeting, immune response, adhesion), 
which may subsequently influence the efficiency of growth factor bioactivity [122, 123].  
Previous research has shown that the surface topography of a material at either the nano- 
or micro-scales can alter the differentiation capabilities of osteogenic lineage cells [116, 
124-126].  Many of the current BMP-2 delivery systems have focused on physical 
properties to meet the structural and mechanical requirements of bone regeneration.  
Recently, however, research has also focused on developing BMP-2 delivery systems 
with considerations for both biochemical and physical properties of the carrier. 
Many different carriers have been developed for BMP-2, including the collagen 
carrier FDA approved for use in the Medtronic InFUSE™product [6, 79, 99].  Other 
BMP-2 carrier materials include PLGA, hydrogels, calcium phosphate (CaP) cement, 
hydroxyapatite (HA), demineralized bone matrix (DBM), and tricalcium phosphate 
(TCP) [8, 17, 83, 127-129].  These carrier systems allow for some control of the BMP-2 
released and have been shown to improve BMP-mediated differentiation and 
mineralization in vitro and in vivo.  However, some of these systems utilize harsh 
 25 
chemical treatments during fabrication or still require large doses to induce a response.  
The work presented in this thesis examines different delivery methods for BMP-2 in 








Sustained release systems have previously been developed for the use of growth 
factors in tissue engineering therapies.  However, many of these systems continue to have 
limitations associated with low loading efficiencies and minimal biological activity after 
release.  This aim focused on employing a previously developed lipid-based microtube 
delivery system for the sustained release of bone morphogenetic protein-2 (BMP-2).  The 
lipid microtubes were fabricated using a self-assembly method, thus avoiding the use of 
harsh organic solvents that may cause damage to the protein.  The microtubes were 
loaded with BMP-2 by rehydrating lyophilized microtubes in a concentrated BMP-2 
solution and the subsequent release kinetics was measured using in vitro immunoassays.  
The capacity of this system to deliver biologically active BMP-2 was assessed in vitro 
using alkaline phosphatase assays, Von Kossa staining, and quantitative real time RT-
PCR for osteogenic gene expression in human mesenchymal stem cell (hMSCs).  The 
results demonstrated that the lipid microtube system provided sustained delivery of 
biologically active BMP-2, determined by the ability to enhance osteogenic 
differentiation over the control groups.  However, when the sustained delivery system 
was compared to the delivery of a bolus dose of BMP-2, no significant advantage for cell 
differentiation was observed over the bolus. 
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3.2  Introduction 
The interdisciplinary field of tissue engineering presents promising therapies to 
repair tissue and restore physiological function, with the potential to address many of the 
difficulties and limitations associated with grafting procedures. Tissue engineering 
therapies may include a combination of cell, protein, or gene therapies to restore and 
regenerate physiological tissue function.  In particular, protein or growth factor therapies 
have shown promise in tissue engineering therapies due their highly specific actions [8, 
82].  Growth factors have the ability to induce a variety of cell functions vital to tissue 
repair, such as proliferation, migration, and differentiation.  However, protein therapies 
often require frequent injections at high doses to overcome poor protein stability, making 
these treatments dangerous to the patient and very expensive [9, 130].  Sustained delivery 
systems that are able to optimally control the rate and location of growth factor release, 
while also maintaining a concentration level within therapeutic limits are necessary in 
order to provide growth factor therapies safely and effectively to patients [131].   
Existing growth factor delivery systems include lipid-based and polymeric 
vehicles [19, 132].  However, the fabrication processes of many of these systems often 
involve the use of harsh organic solvents, which may denature and deactivate sensitive 
proteins, resulting in low loading efficiencies and reduced bioactivity [9, 112, 120, 129].  
Another limitation associated with current delivery systems is the occurrence of a large 
burst release of the growth factor soon after implantation [25, 132].  This release profile 
may not be optimal for tissue repair since the surrounding tissue sometimes requires 
prolonged exposure to the growth factor [133]. 
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Bone morphogenetic proteins (BMPs) have been utilized widely in bone tissue 
engineering because of their ability to initiate and maintain the entire bone formation 
cascade (i.e. chemotaxis, proliferation, and differentiation) [8, 9, 82, 84, 85, 134, 135].  
However, delivery of BMPs has been challenging due to the short half-life and rapid 
diffusion from the treatment site.  Efforts to sustain BMP-2 activity have previously been 
approached by incorporating the protein in degradable carriers and/or co-delivery with 
other factors.  The current carrier materials include collagen, tricalcium phosphate, 
demineralized bone matrix, hydrogels, and synthetic polymers [8, 9, 83, 134].  The 
delivery of BMP-2 in an absorbable collagen sponge is FDA approved for use in tibial 
fractures and spinal fusions.  However, this system still requires large doses of BMP-2 at 
high costs and has unpredictable pharmacokinetic profiles [83, 103, 134].  Therefore, 
further development of carrier systems with consistent results and reduced doses is 
required.   
Previous research has shown BMP-2 expression to vary spatially and temporally 
during fracture healing, with higher concentrations occurring in mature and hypertrophic 
chondrocytes and areas of active bone formation [64, 84, 86, 135].  However, the specific 
time period and mode of localization for optimal BMP-2 activity is still unclear. A carrier 
system may be designed to provide sustained, localized delivery of BMP-2 within the 
therapeutic limits throughout the course of tissue regeneration, ensuring that BMP-2 is 
present during the optimal time to induce a cell response [3, 83, 130].   
The goal of this study was to establish if sustained release of BMP-2 from a lipid-
based microtube delivery system would significantly enhance in vitro mineralization of 
human mesenchymal stem cells (hMSCs) in comparison to controls, empty microtubes, 
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and a bolus dose of BMP-2.  The lipid-based microtube vehicle used in this study was 
previously developed for the delivery of neural growth factor, transforming growth 
factor-ß, and brain derived neurotrophic factor [120, 136, 137].  Lipid microtubes are a 
unique delivery system due to the self-assembly method used to fabricate this carrier 
system, which avoids the use of organic solvents, heat, and other harmful procedures that 
are often involved in processes utilized to produce growth factor delivery systems [5, 
120, 138, 139].  These microtubes are also beneficial because they can either be injected 
for minimally invasive procedures or suspended in three dimensional gel structures for 
implantation [120, 136].  The hypothesis was that the lipid microtubes would provide 
sustained release of biologically active BMP-2, thereby enhancing mineralization of 
hMSCs.  To test this hypothesis the system was analyzed using in vitro assays to monitor 
the release kinetics and bioactivity of BMP-2, and subsequently compare the sustained 
delivery system with a bolus dose.   
3.3 Materials and Methods 
3.3.1 Lipid microtube fabrication 
 Lipid microtubes were prepared using a self-assembly method described by 
Meilander et al. [120].  First, 10 mg of DC8,9PC lipid (Avanti Polar Lipids, Alabaster, 
AL, USA) (Figure 3.1) was dissolved in 10 ml of 70% ethanol at 55ºC.  The lipid 
solution was held at 55ºC for 6 hours and then slowly cooled to 25ºC in a 
microprocessor-controlled refrigerated water bath (Isotemp Refrigerated Circulator, 
Fisher Scientific, Waltham, MA, USA).  The microtubes were then stored at room 
temperature until further use.  See Appendix A for a detailed protocol. 
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Figure 3.1 1,2-bis(tricosa-10,12-diyonyl)-sn-3-phosphocholine (DC8,9PC) (Images 
courtesy of Avanti Polar Lipids, Alabaster, AL, USA) [140] 
 Prior to drying and using the microtubes in assays, the cryoprotectant trehalose 
(Sigma, St. Louis, MO, USA) was added to the solution at a concentration of 50 mM to 
preserve the tubular structure during the drying process.  The microtubes were then 
washed in PBS and collected by centrifugation (1500 g, 10 min).  Remaining solution in 
the microtubes was removed by lyophilization. 
3.3.2 Characterization of lipid microtube dimensions and degradation 
An aliquot of microtubes was placed on a glass slide with a cover slip to create a 
single layer of microtubes.  The microtubes were imaged using a Zeiss Axiovert light 
microscope connected to an AxioCam digital camera (Carl Zeiss, Inc., Thornwood, NY, 
USA) and desktop computer running AxioVision software.  The lengths of microtubes in 
at least 5 fields of view were traced from the captured images using the AxioVision 
software.  The yield of microtubes was calculated from a dilution of microtubes counted 
on a hemocytometer.  
To monitor the degradation, microtubes were incubated in 500 µl of phosphate 
buffered saline (PBS) or α-MEM (Invitrogen, Carlsbad, CA, USA) with 16% fetal calf 
serum (Atlanta Biologicals, Atlanta, GA, USA) and 2 mM L-glutamine, 100 units 
penicillin, and 100 µg streptomycin (Invitrogen).  At the respective time points an aliquot 
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of microtubes was collected and the lengths were measured using the light microscope as 
described previously.   
3.3.3 Protein loading and release kinetics 
The microtubes were loaded with recombinant human BMP-2 (CHO-derived, 
carrier free, R&D Systems; Minneapolis, MN, USA) by rehydrating the dried microtubes 
in 40 µl of protein solution per mg of lipid.  The microtubes were allowed to incubate in 
the protein solution overnight at 8°C.  Unencapsulated growth factor was separated from 
the microtubes by centrifugation and collected for assay with an rhBMP-2 enzyme-linked 
immunosorbent assay (ELISA; R&D Systems).  The loading efficiency was measured 
using microtubes that were counted on a hemocytometer and diluted to known 
concentrations.  The microtubes were then incubated overnight in BMP-2 solution at a 
concentration of 2 µg/ml.  The unencapsulated protein was separated from the microtubes 
by centrifugation and collected for assay with an ELISA (R&D Systems).  
Microtubes loaded with BMP-2 were incubated in 500 µl of PBS to monitor the 
release kinetics.  The microtubes were then separated by centrifugation and the 
supernatant was collected and stored at -20°C until assay.  Microtubes were resuspended 
in 500 µl of fresh PBS at each time point.  The amount of BMP-2 released was measured 
using an ELISA. 
3.3.4 Bioactivity assay 
 The bioactivity of released BMP-2 was analyzed by determining its ability to 
induce alkaline phosphatase activity in human mesenchymal stem cells (hMSCs).  
Human mesenchymal stem cells, kindly provided by Tulane University, were harvested 
from bone marrow aspirates.  Cells were passaged twice in α-MEM containing 16% FBS 
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(Atlanta Biologicals), 2 mM L-glutamine, 100 units penicillin, and 100 µg streptomycin 
(Invitrogen).  The hMSCs were subcultured at a low density (500 cells/cm2) and not 
allowed to expand past 70% confluency.  The hMSCs were then trypsinized, counted, and 
seeded in collagen-coated 24-well tissue culture treated plates at a density of 10,000 
cells/cm2.  The cells were allowed to reach confluency, usually requiring 1-2 days post-
seeding.  The cells were then differentiated in media supplemented with 6mM ß-
glycerophosphate, 50 µg/ml ascorbic acid 2-phosphate (Sigma) (Appendix B).  Cells 
layers were collected and analyzed at 7 and 28 days for alkaline phosphatase (ALP) 
activity.  ALP activity was quantified using the p-nitrophenylphosphate method.  Briefly, 
cell layers were washed with PBS, lysed with 0.1% TritonX-100/PBS and subjected to 
three freeze-thaw cycles to thoroughly disrupt the cell membranes.  Subsequently, 50 µl 
of the supernatant was incubated with 50 µl p-nitrophenylphosphate solution (Sigma) for 
30 minutes to 2 hours at 37ºC.  The reaction was stopped by adding 100 µl 1M NaOH 
and the absorbance was read at 405 nm using a colorimetric plate reader.  ALP activity 
was normalized to total DNA content.  DNA content from cell lysates was quantified 
using the Pico Green® dsDNA Quantitation Kit (Molecular Probes).   Briefly, samples 
from the cell lysates were added to a black 96-well plate in triplicate and incubated for 5 
minutes with the Pico Green® working solution.  The 96-well plate was then read on a 
fluorescent plate reader at an excitation of 485-nm, emission of 535-nm and manual gain 
of 60.  Sample intensities were compared to a standard curve of known dsDNA 
concentrations.  
Cell layers were also analyzed for phosphate deposits with the Von Kossa staining 
technique at 4 weeks.  Cells were fixed in 70% ethanol and incubated under UV light 
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with 5% silver nitrate (Sigma) solution for 10 minutes.  The cell layers were then rinsed 
in distilled water and treated with 2.5% sodium thiosulfate for 2 minutes.   
Sustained delivery was compared to a bolus dose.  Equivalent doses of BMP-2 
(100 ng/ml) were either delivered encapsulated in the microtubes or as a bolus dose.  The 
bolus dose was removed after 48 hours.  BMP-2 microtubes were collected and reused 
throughout the study.  
3.3.5 RNA isolation and quantitative RT-PCR 
Cells monolayers were rinsed with PBS and then scraped from the tissue culture 
plates and stored in 500 µl RNAlater (Ambion, Austin, TX, USA) at -20°C.  Cell pellets 
were then separated by centrifugation and resuspended in RLT buffer (Qiagen, Valencia, 
CA, USA) with 1% ß-mercaptoethanol (Sigma) and disrupted by passing through a 
Qiashredder (Qiagen) according to the manufaturer’s protocol.  RNA was isolated using 
the RNeasy spin columns (Qiagen) according to the manufacturer’s protocol.  RNA was 
quantified with a Nanodrop® ND-1000 spectrophotometer system.  The RNA was then 
converted to cDNA using the Superscript III kit (Invitrogen).  Samples were analyzed for 
alkaline phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN), and Runx2 
mRNA levels using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) on a Bio-
Rad iCycler iQ5 real-time PCR instrument using the sequences listed in Table 3.1 
(Integrated DNA Technologies, Inc., Coralville, IA, USA) [32, 141].  Template 
concentrations from cDNA solutions were quantified using a linear standard curve of 
known template concentrations.  Transcript levels were then expressed as femtomoles of 
transcript and normalized to total µg RNA. All results were confirmed to be the 
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amplification of a single transcript product by the presence of a single peak in the melt 
curve. 
Table 3.1 Quantitative real-time PCR primers (5’ to 3’ direction) 
Gene  Forward Reverse 
Alkaline phosphatase CGTGGCTAAGAATGTCATCATGTT TGGTGGAGCTGACCCTTGA 
Bone sialoprotein II GGCCTGTGCTTTCTCAATGAA GCCTGTACTTAAAGACCCCATTTTC 
Osteocalcin GCAAAGGTGCAGCCTTTGTG GGCTCCCAGCCATTGATACAG 
Runx2 TGATGACACTGCCACCTCTG GGGATGAAATGCTTGGGAAC 
 
3.3.6 Statistical analysis 
 All data are presented as the mean ± standard error of the mean (SEM), unless 
otherwise stated.  Statistical analysis was done using Prism 5 software (GraphPad 
Software, Inc., San Diego, CA, USA).  Groups were compared using an ANOVA and 
Tukey’s post hoc analysis for pairwise comparisons, with a p-value<0.05 considered 
statistically significant.  Other statistical analyses used are stated in the results.  When 
required, raw data was transformed using a logarithmic transformation to make the data 
normal and the variance independent of the mean [142, 143].   
3.4  Results 
3.4.1 Characterization of lipid microtube dimensions and degradation  
The microtubes fabricated using the self-assembly method had an average length 
of 30 ± 14.71 µm (mean ± standard deviation, Figure 3.2) and median length of 27.82 
µm.  Over 75% of the microtubes had lengths between 10 and 40 µm, and nearly 20% of 
the microtubes were 40-70 µm.  However, a small portion (less than 1%) of the 
microtubes reached lengths over 100 µm.  Typically, 10 mg of DC8,9PC lipid yielded 
approximately 6x108 microtubes. 
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Figure 3.2 Lipid microtube characteristics.  Representative light microscope image (top) 
of DC8,9PC lipid microtubes fabricated using the self-assembly method described by 
Meilander et al. [120].  Length distribution (bottom) of lipid microtubes measured from 
microscope images, average length of 30 ± 14.71 µm (mean ± SD). 
Degradation was expected to occur from the ends of the microtubes due to the 
open lipid chains available to hydrolysis.  This was confirmed by measuring the lengths 
of the microtubes incubated in cell culture media or PBS and performing a Kruskal-
Wallis test for non-Gaussian distributions to determine if the distribution in lengths were 
significantly different.  The lengths of the microtubes incubated in both PBS and media 
significantly decreased from day 0 to day 21 (p<0.0001), with the average lengths 
decreasing from 30 ± 15 µm to 17 ± 10 µm (Figure 3.3A).  Microtubes in PBS appeared 
to degrade quicker than microtubes in media, with a significant decrease (p<0.0001) in 
lengths at each time point until day 10.  Whereas microtubes in media had a slightly more 
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delayed degradation with no significant decrease in lengths until day 7 (p<0.0001).  
Although the microtubes in PBS degraded faster initially and had significantly shorter 
lengths than microtubes in media at days 4 and 10 (p<0.0001), by day 21 there was no 
difference in lengths of the microtubes in either solution.  The microtubes had a tendency 
to aggregate in cell culture media due to the negatively charged ions exposed on the 
lipids during hydrolysis and the cations present in the media (Figure 3.3B). 
 
Figure 3.3 Lipid microtube degradation.  (A) Average lengths of lipid microtubes 
incubated in PBS or media, measured from microscope images obtained at respective 
time points.  Lengths decreased by approximately 50% during the 21-day period 
(p<0.0001). (B) Representative microscope images of microtubes after 4 days either in 
PBS or cell culture media conditions. 
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3.4.2 Protein loading and release kinetics 
BMP-2 was effectively loaded into the microtubes.  The loading capacity was 
represented as a ratio of the amount of protein encapsulated to the total amount of protein 
initially added to the microtubes (Figure 3.4). As expected, the amount of 
unencapsulated protein decreased with an increase in microtube concentration due to a 
larger available volume from the increasing microtube population.  The lowest 
concentration of microtubes (1x107) encapsulated significantly less protein than all other 
microtube concentrations (p<0.0001).  At concentrations above 4x107 microtubes there 
was no significant decrease in unencapsulated protein indicating that there is a limit of a 
90% loading capacity.    
BMP-2 was then loaded into 10 mg of microtubes to monitor the release kinetics.  
Protein was released from microtubes for at least two weeks without a large initial burst 
release (Figure 3.5).  Approximately 40% of the initial protein loaded was released over 
this period. The cumulative release was calculated as a ratio of the initially loaded 
protein, which was estimated using the approximate volume of microtubes and the 
concentration of the loading solution. 
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Figure 3.4 Loading capacity in relation to quantity of microtubes, represented as the ratio 
of unencapsulated protein to total protein added to the microtubes (n=3). 
 
 
Figure 3.5 Release kinetics of BMP-2 measured with ELISA.  Cumulative release 
calculated as the total amount released divided by the quantity of initially loaded BMP-2 
(n=4). 
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3.4.3 Cell viability 
 Cell viability in the presence of microtubes was assessed using a LIVE/DEAD® 
Viability Kit (Invitrogen, Carlsbad, CA) to fluorescently label hMSC monolayers and 
imaged with a fluorescent microscope for viable cells (Calcein label—green) and dead 
cells (Ethidium homodimer label—red) (Figure 3.6).  The images showed a minimal 
number of dead cells at all time points for each group.  The highest concentration of 
microtubes had a larger number of dead cells at days 14 and 28 than all other groups, 
however the majority of the cells remained viable.  DNA content was also not greatly 
affected by the presence of the lipid microtubes, measured by the Pico Green DNA 
quantification assay (Figure 3.7).  DNA content at the highest concentration of 
microtubes (24x105 tubes/ml) was significantly less than the control (0 tubes/ml) only at 
day 14.  However, by day 28 DNA content for the high concentration of microtubes 
significantly increased and was no longer less than the control.  This indicates that the 
increase in cells was simply delayed by the high concentrations of microtubes, and cell 
number was not overall substantially hindered. 
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Figure 3.6 Cell viability in the presence of lipid microtubes.  Microscope images of 
hMSC monolayers stained with a LIVE/DEAD® Viability Kit (RED = dead cells, 
GREEN = live cells; magnification 4x, scale bars = 200 µm). 
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Figure 3.7 DNA quantification of hMSCs in culture with increasing concentrations of 
lipid microtubes (ANOVA: ★ p<0.05 compared to the control (0 tubes/ml) within each 
time point; $ p<0.05 compared to the same group at the previous time point; n=4). 
3.4.4 Post-release bioactivity assay 
To ensure the BMP-2 released from the microtubes remained biologically active, 
the ALP activity of hMSCs was measured.  The results demonstrate that BMP-2 releasing 
microtubes had significantly higher levels of alkaline phosphatase activity at 28 days 
compared to control microtubes (p<0.01), indicating a release of bioactive BMP-2 from 
the microtubes (Figure 3.8).  Additionally, hMSCs in the presence of BMP-2 releasing 
microtubes had a significant increase (p<0.0001) in ALP activity from day 7 to day 28.  
The control PBS-loaded microtubes also significantly increased (p<0.01) from day 7 to 
day 28, however to a less extent than the BMP-2 microtubes.  
Matrix mineralization was confirmed with von Kossa staining for phosphate 
deposits at day 28.  Stained cell monolayers showed more phosphate deposits when 
hMSCs were cultured in the presence of BMP-2 releasing microtubes (Figure 3.9).  
These phosphate deposits exhibited nodule formation, indicating osteogenic 
differentiation of the hMSCs.  Fewer mineralized regions were observed in monolayers 
treated with control microtubes. 
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Figure 3.8 Alkaline phosphatase activity in hMSCs, measured by the p-
nitrophenylphosphate assay, in response to BMP-2 releasing microtubes or control 
microtubes (n=6).  Un-paired t-test: ★ p<0.01; each group is significantly different 
between time points (p<0.01 control tubes, p<0.0001 BMP-2 tubes). 
 
Figure 3.9 Von Kossa staining of hMSC monolayers after 28 days in culture with control 
or BMP-2 microtubes, scale bars = 100 µm. 
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3.4.5 Sustained release versus bolus dose of BMP-2 
Further assessment of the efficacy of this system compared the differentiation of 
hMSCs in the presence of a bolus BMP-2 dose or BMP-2 releasing microtubes.  The 
bolus BMP-2 dose was equivalent to the total amount of BMP-2 encapsulated in the 
microtubes.  ALP activity was assessed at 7 and 28 days after bolus BMP-2 or BMP-2 
microtubes were added to the cell culture media (Figure 3.10).  After 7 days, the cells 
incubated with BMP-2 microtubes had significantly lower ALP activity than all other 
groups (p<0.01) and the bolus BMP-2 group was significantly lower than the control 
microtubes (p<0.01).  Between day 7 and 28 the ALP activity in cells with bolus BMP-2 
and BMP-2 microtubes increased significantly (p<0.0001).  However, only the cells 
exposed to the bolus dose of BMP-2 had significantly higher ALP activity at 28 days than 
the cells incubated with control microtubes.   The ALP activity at day 28 in cells 
incubated with BMP-2 microtubes remained higher than the control microtubes, however 
the differences detected by the ANOVA were not significant in this case. 
 
Figure 3.10 ALP activity in hMSCs, measured by the p-nitrophenylphosphate assay, in 
response to bolus dose BMP-2, BMP-2 microtubes or control microtubes (n=6).  
ANOVA: ★ p<0.01 within time-point.  All groups significantly increased from day 7 to 
day 28 (un-paired t-test: p<0.01). 
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Gene expression was analyzed with RT-PCR at 7 and 28 days after bolus BMP-2 
or BMP-2 releasing microtubes were added to the cell culture media.  Expression levels 
for the osteogenic matrix proteins (bone sialoprotein, osteocalcin), transcription factor 
(Runx2), and mineralization-associated enzyme (alkaline phosphatase) were determined 
from linear standard curves (Figure 3.11).  The bolus dose of BMP-2 significantly 
increased alkaline phosphatase, bone sialoprotein, and osteocalcin mRNA expression by 
day 28.  BMP-2 microtubes significantly increased osteocalcin expression by day 7, 
however the level of osteocalcin expression remained the same at day 28 and was 
significantly lower than the expression in the cells exposed to the bolus dose.  BMP-2 
microtubes increased Runx2 expression compared to the control, however the control 
microtubes also increased Runx2 expression compared to the control.  Therefore, the 




Figure 3.11 Osteogenic gene expression in response to bolus dose and BMP-2 
microtubes.  mRNA transcript levels were assessed by real time RT-PCR analysis for 
osteoblastic markers including alkaline phosphatase (ALP), bone sialoprotein (BSP), 
osteocalcin (OCN), and Runx2; (n=6).  Data presented as femtomoles of mRNA 
transcript normalized to µg of total RNA.  ANOVA: p<0.05 within each time-point  
versus control,  versus control tubes,  versus bolus BMP-2, ★ versus BMP-2 tubes. 
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Differences in matrix mineralization were assessed with von Kossa staining for 
phosphate deposits at day 28.  Stained cell monolayers showed more phosphate deposits 
when hMSCs were cultured in the presence of BMP-2, either as a bolus or released from 
the microtubes (Figure 3.12).  These phosphate deposits exhibited nodule formation, 
indicating osteogenic differentiation of the hMSCs.  However, there were no large 
differences in matrix mineralization observed between the bolus BMP-2 and BMP-2 
microtubes groups.  Fewer mineralized regions were observed in control monolayers. 
 
Figure 3.12 Von Kossa staining of hMSC monolayers after 28 days in culture to compare 
bolus BMP-2 and BMP-2 releasing microtubes, scale bars = 200 µm. 
3.5  Discussion 
Critical issues for effective therapeutic protein delivery include the stability of the 
proteins, time or duration of exposure, and effective dose.  This has led researchers to 
develop sustained and controlled delivery systems [9].  However, the fabrication 
processes used for many of these carriers are extremely harsh and unfavorable for protein 
structure and function [9, 112, 120]. Additionally, many other sustained release systems, 
such as nanoparticles and microparticles, have unpredictable or unknown loading 
capacities leading to inconsistent results [24, 144-149].  In this study we utilized a lipid 
microtube system developed by Meilander, et al. for growth factor delivery [120].  
However, the efficacy of these microtubes as a delivery vehicle may be growth factor 
dependent.  We demonstrated the response of hMSCs to the sustained release of BMP-2 
using the lipid microtube delivery system for bone tissue engineering applications.  We 
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found that although the microtubes provided sustained release of bioactive BMP-2, there 
was no significant benefit for hMSC differentiation over exposure to a bolus dose.   
 Lipid microtubes were successfully fabricated using the self-assembly method 
previously described, with an average length of 30 ± 15 µm [120, 138].  Although the 
large dimensions of the microtubes restrict their use for drug delivery applications in the 
vasculature (i.e. injectable delivery), they are suitable for applications in which localized 
delivery within tissues is desirable.  The large size will also restrict endocytosis by cells 
in the surrounding tissue, which is a process that may render a drug inactive due to the 
external localization of some receptors on the cell membrane.  Smaller drug delivery 
systems, such as nanoparticles, can be quickly taken up by cells, resulting in the release 
of the drug within the cell [150, 151].  Although this may not be a problem for drugs with 
intercellular receptors, such as steroid hormones or gene therapies, BMP-2 requires 
binding to extracellular domains of the BMP receptors [95, 152].   
The microtubes were observed to degrade from the ends, as indicated by the 
significant decrease in average length.  Carlson, et al. suggested that the degradation of 
DC8,9PC lipid microtube structures is dominated by the heterogenous bilayer packing at 
the open microtube ends [153].  However degradation is not limited to the open ends and 
can occur at any location of non-uniform bilayer packing along the walls of the 
microtubes where the lipid molecule is exposed to potential hydrolytic activity [153].  
Due to this hydrolytic degradation, the microtubes were observed to form aggregates in 
the cell culture media as the negatively charged fatty acids produced during hydrolysis 
were electrostatically attracted to cations and other positively charged molecules in the 
media [138].  
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Sustained release of BMP-2 from the lipid microtubes was observed for at least 
two weeks without a large initial burst release, as shown by the release profile.  Other 
studies have shown that these microtubes provide release for over 50 days [154].  
Meilander, et al. determined that molecular weight of the loaded protein affects the rate 
of release, with smaller molecules releasing faster than the larger molecules [120].  It was 
also shown that the higher concentrations of protein initially loaded in the microtubes 
caused a larger amount to be released each day [120].  This leads to the ability to more 
accurately assess the performance of the delivery system and potentially predict the 
release of various proteins.   
The viability of hMSCs was not substantially affected in the presence of high 
concentrations of lipid microtubes.  Previous studies have shown that lipid microtubes 
were biocompatible and safe for use in in vitro tissue culture experiments [120].  Other 
research has also shown that implanting microtubes for in vivo rodent assays did not 
induce a significant inflammatory response as compared to saline injections [120, 136].  
Some polymeric delivery systems have demonstrated chronic inflammatory responses 
and low biocompatibility due to the biproducts resulting from degradation as well as 
residual chemicals from the fabrication process [155].  The lipid microtube system avoids 
both of these criteria, with free fatty acids being produced during degradation and no 
harsh chemicals used during fabrication. 
 BMP-2 released from the microtubes was able to increase alkaline phosphatase 
(ALP) activity in hMSCs after four weeks in culture compared to cells incubated with 
control microtubes, indicating that the microtubes provided sustained release of 
biologically active BMP-2 [156].  However, ALP activity was not significantly different 
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when compared to a bolus dose of BMP-2.  BMP-2 microtubes also did not significantly 
increase gene expression compared to a bolus dose of BMP-2.  The results seen in ALP 
activity and osteogenic gene expression may be due to the response of hMSCs to 
different kinetics of BMP-2 exposure and lower concentrations of BMP-2 released from 
the microtubes [157].  Although the initial dose of BMP-2 loaded in the microtubes was 
equivalent to the bolus dose, the cumulative exposure of BMP-2 released from the 
microtubes was lower than the bolus dose.  Previous research has shown that 
osteoinduction is dependent on the pharmacokinetics of the BMP-2 delivery system [16, 
128, 129, 158, 159].  Maeda, et al., demonstrated that faster releasing systems resulted in 
more bone formation in vivo, while other work has shown that a burst release followed by 
a sustained release profile is more beneficial [16, 158-160].  
The poor stability of the BMP-2 structure upon release from the microtubes may 
also contribute to the reduced osteogenic activity. BMP-2 structure and bioactivity is 
known to be highly sensitive to environmental conditions (i.e. temperature, pH, 
solubility, proteolytic degradation) [96, 161].  While encapsulated in the microtube 
system, BMP-2 is protected from many of the factors that denature or deactivate the 
protein.  However, upon release from the microtubes, BMP-2 is subject to all of the 
adverse environmental factors that have been shown to damage the protein and reduce its 
bioactivity.  This rapid degradation of the protein can cause the bioactivity of the small 
amount of released BMP-2 to be reduced, resulting in minimal signaling to induce a cell 
response.  We showed that a dose greater than 25 ng/ml is required in order to induce a 
significant osteogenic response in hMSCs in vitro (Appendix C). In addition to the poor 
stability of BMP-2 upon release from the microtubes, the encapsulation within the 
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microtubes does not fully protect the BMP-2 from denaturing conditions such as 
temperature.  Therefore, even while the BMP-2 is encapsulated within the microtubes, it 
is potentially subject to denaturing and subsequent reduced bioactivity.  The drastic 
reduction of BMP-2 bioactivity can be taken into consideration when designing a future 
sustained delivery system, with the possibility of co-delivering BMP-2 and stabilizing 
factor, such as heparin.  Zhao, et al., showed that the half-life of BMP-2 was only 1-3 
hours in vitro, but could be prolonged 20-fold by using protective agents such as heparin 
and other sulfated polysaccharides [96].  
Previous research has indicated that sustained release at low doses will be more 
effective than a large bolus dose, and will pose a lower risk of side effects [3, 133].  The 
aim of this study was to determine if sustained release of BMP-2 from the lipid microtube 
system would provide a significant benefit to inducing mineralization compared to the 
current clinical standard, which usually provides a large bolus dose of BMP-2 to the 
surrounding tissue.  The lipid microtube sustained delivery system was designed to 
acquire prolonged exposure of BMP-2, with the expectation that sustained delivery of 
BMP-2 will result in greater mineralization.  However, the prolonged exposure to lower 
amounts of BMP-2 did not exhibit a significant improvement over a brief exposure to a 
larger dose of BMP-2 in the differentiation response of hMSCs.  Some research has 
suggested that a burst release followed by sustained release of BMP-2 is most desirable 
[100].  Nevertheless, the efficacy of the lipid microtube delivery system is protein 
dependent and may still be beneficial for applications that have low therapeutic 
concentration requirements, as was previously shown for the delivery of brain-derived 
neurotrophic factor (BDNF) [136].   
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3.6  Conclusions 
 In this study, we characterized the sustained release of BMP-2 from lipid 
microtubes and showed that the biological activity is retained after release from the 
microtubes.  These results indicate that lipid microtubes can be used to provide sustained 
release of BMP-2 for bone tissue engineering.  However, sustained delivery of BMP-2 
was not sufficient to significantly enhance osteogenic differentiation compared to a bolus 
dose over a 28-day period.  These data suggest that the microtube sustained delivery 
system is able to deliver active BMP-2, however the sustained release of low doses may 
not be significantly advantageous.  Another approach for BMP-2 delivery will be 





INCORPORATION OF HEPARIN IN A COLLAGEN MATRIX TO 
IMPROVE BMP-2 RETENTION AND BIOACTIVITY 
 
4.1 Abstract 
 The binding affinity of BMP-2 and the current FDA approved collagen carrier is 
low, resulting in rapid diffusion from the implant in vivo.  This can cause ectopic bone 
formation in surrounding tissues as well as other systemic effects.  Research has recently 
concentrated on improving the affinity of BMP-2 to the carrier material.  The focus of 
this aim was to incorporate heparin in a collagen matrix to improve the retention and 
bioactivity of BMP-2 for bone tissue engineering applications.   The ability to retain 
BMP-2 and the osteoinductive capacity of this delivery system was assessed in vitro 
using immunoassays and confocal microscopy to quantify BMP-2 content, and micro-CT 
analysis of cell-mediated mineralization.  The results indicate that incorporation of 
heparin in the collagen matrix improves BMP-2 retention.  This corresponded to slower 
release kinetics from collagen/heparin matrices.  Three-dimensional mineralization of 
hMSCs was also significantly enhanced when heparin and BMP-2 were present in the 
collagen matrix.  These results indicate that incorporating heparin in the collagen matrix 
improves BMP-2 retention, delays the release, and potentiates the bioactivity in vitro.  
Therefore, incorporation of heparin in a collagen matrix for the delivery of BMP-2 may 
be beneficial for bone tissue engineering.     
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4.2 Introduction 
Growth factor therapies have gained considerable attention in recent years 
because of their highly specific activity and ability to induce a variety of cell functions 
vital to tissue repair, such as proliferation, migration, and differentiation.  However, 
proteins often have low stability and rapidly diffuse from the treatment site, resulting in 
frequent injections at high doses.  In Specific Aim I, we demonstrated that the sustained 
delivery of BMP-2 in a lipid microtube system was able release biologically active BMP-
2, but the sustained release system did not provide a significant benefit compared to a 
bolus dose.  These results indicate that a different type of delivery system may be more 
beneficial for BMP-2 therapies. 
BMPs have been used in combination with various carrier materials in efforts to 
efficiently deliver and retain the BMP molecule at the treatment site.  These carrier 
materials mainly include collagen and demineralized bone matrix (DBM) [15, 16].  Yet, 
few delivery approaches have addressed the biological interactions between BMP-2 and 
the carrier, and have mainly been designed to meet structural/biomechanical and 
immunogenic requirements.  Currently, the FDA has only approved collagen as a carrier 
for BMP-2.  Yet research has shown that BMP-2 has low affinity for collagen, leading to 
rapid diffusion from the construct [15].  Researchers have claimed that BMP-2 mediated 
bone formation not only depends on the initial concentration of BMP-2, but also is 
largely controlled by the subsequent retention within the carrier [15, 159].   Therefore, 
recent efforts have focused on enhancing the binding affinity of BMPs either by 
immobilizing heparin or other ECM molecules in the carrier, or biochemically altering 
the BMP-2 molecule [17, 20, 21]. 
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BMPs were originally isolated from demineralized bone matrix using heparin 
affinity columns due to their inherent binding properties [162]. In addition to the high 
binding affinity, research has suggested that heparin is involved in BMP-mediated 
differentiation [17, 95, 96, 117, 163].  This effect has been shown to be in part due to 
heparin promoting protein-receptor binding with higher specificity and maintaining the 
structural conformation necessary for receptor-ligand binding [95, 117].  Heparin has also 
been shown to protect the ligand from suppression by antagonists such as noggin and 
chordin [96, 164]. 
Heparin is a sulfated polysaccharide, which is located on the cell surface as well 
as in the bone extracellular matrix (ECM).  It is known to be a potent stimulator of 
proliferation in human mesenchymal stem cells (hMSCs) [112, 163]. Low molecular 
weight heparins have been shown to enhance osteoblast differentiation in a dose 
dependent manner by serving as a multifunctional regulator of growth factors expressed 
during bone repair [96, 112, 117, 163, 165].  These attributes of heparin may prove to be 
useful for bone tissue engineering. 
Heparin has been used as an anti-coagulant and as a preventative treatment for 
thromboembolic episodes after orthopedic surgeries [166].  Without treatment, deep vein 
thrombosis occurs in 50-70% of patients that have undergone total hip arthroplasty, total 
knee arthroplasty, acute fixation of hip fractures, and in patients that have acute spinal 
cord injury or multiple injuries [166].  However, standard unfractionated heparin has 
been shown to have deleterious effects on bone formation when administered daily [166-
168].  These effects include osteoporosis, increased calcium loss, and decreased bone 
turnover.  Low molecular weight heparins, derived from unfractionated heparin, reduce 
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these risks by about 50% without the side effects seen with standard unfractionated 
heparin and have become the standard treatment for thromboembolism, [166, 169].  
However, high doses of low molecular weight heparin administered daily can reduce 
cancellous bone volume and delay fracture healing [166].  Therefore, these effects must 
be considered when designing growth factor delivery systems that utilize heparin. 
Crystal structure analyses indicate that heparin directly binds BMP-2 via 
electrostatic interactions among the negatively charged sulfate groups on the heparin 
molecule and the high concentration of positively charged amino acid residues at the N-
terminus of BMP-2 [95, 117, 164, 170, 171].  Approximately 5-6 BMP-2 molecules can 
bind one heparin molecule with dissociation constant (Kd) of about 15-20 nM [95].  
Ruppert, et al. showed that an 11 amino acid sequence at the N-terminus is critical for 
heparin binding, but this region is outside the cysteine rich area necessary for receptor 
binding, therefore does not inhibit receptor binding (Figure 4.1) [95].  This N-terminus 
region normally causes non-specific binding of BMP-2 to other receptors, however, when 
this region is bound to heparin, BMP-2 is able to bind more specifically to the BMP 
receptor [95].  Heparin binding also improves growth factor activity by inducing a 
conformational change in the proteins, leading to higher resistance to thermal denaturing, 
enzymatic degradation, and inactivation at acidic pH [172].  
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Figure 4.1 Dimerized BMP-2 structure with heparin binding sites indicated by the space-
filling structures.  Protein structure generated using PyMOL Molecular Viewer software 
with amino acid sequences acquired from the Protein Data Bank [95, 171]. 
A major limitation of current clinical BMP-2 treatments is the rapid diffusion 
from the implant site, causing a significant decrease in local concentration.  Furthermore, 
soluble or free BMP-2 loses its bioactivity quickly due to enzymatic degradation and 
other physiologic conditions (i.e. pH, temperature, salt concentration).  Studies have 
shown that immobilized growth factors retain their biological function and remain 
localized to the surface of the construct [26, 173, 174].  Research is currently 
investigating the incorporation or immobilization of heparin into implant materials to 
stabilize and localize heparin-binding growth factors at the implant site [17, 20, 111, 112, 
175, 176].  Additionally, immobilizing heparin to the scaffold retains the heparin 
molecule locally, reducing the side effects caused by systemic exposure to heparin (i.e. 
loss in bone density, abnormal bleeding) [27]. 
The overall goal of Specific Aim II was to develop a delivery system for BMP-2 
utilizing the binding properties with heparin to enhance the retention and osteoinductive 
activity.  A lyophilized collagen matrix previously described by Porter, et al. was 
modified to incorporate heparin for the delivery of BMP-2 [177]. The hypothesis was that 
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BMP-2 would bind with higher affinity to the collagen/heparin matrix, retaining the 
growth factor within the matrix for a longer period of time, thereby enhancing 
mineralization.  To test this hypothesis the system was analyzed using in vitro assays to 
monitor the retention of BMP-2 within the matrix and the bioactivity of BMP-2. 
4.3 Materials and Methods 
4.3.1 Effect of heparin on BMP-2 stability  
 To assess the stability of BMP-2 in the presence of heparin, BMP-2 content 
remaining in the cell culture media after three days was measured using an enzyme-
linked immunosorbent assay (rhBMP-2 ELISA; R&D Systems).  BMP-2 (carrier free, 
CHO cell expressed; R&D Systems) was incubated with low molecular weight heparin 
(porcine intestinal mucosa; Sigma) for 30 minutes prior to adding to cell culture media.  
The cell culture media was then collected from the cell layers after three days and 
assayed with the ELISA. 
4.3.2 Differentiation of hMSCs in the presence of BMP-2 and heparin 
BMP-2 mediated differentiation was analyzed by determining osteogenic gene 
expression in human mesenchymal stem cells (hMSCs).  The hMSCs that Tulane 
University kindly provided were harvested from bone marrow aspirates.  Cells were 
passaged twice in α-MEM containing 10% FBS (Atlanta Biologicals), 2mM L-glutamine, 
100 units penicillin, and 100 µg streptomycin (Invitrogen).  The hMSCs were sub-
cultured at a low density (500 cells/cm2) and not allowed to expand past 70% confluency.  
The hMSCs were then trypsinized, counted, and seeded in collagen-coated 6-well Nunc-
tissue culture treated plates at a density of 10,000 cells/cm2.  The cells were allowed to 
reach confluency, usually requiring 1-2 additional days after seeding.  The cells were 
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then differentiated in media supplemented with 6 mM ß-glycerophosphate and 50 µg/ml 
ascorbic acid 2-phosphate (Sigma) and the additional 100 ng/ml BMP-2 and/or 10 µg/ml 
heparin.  Cells layers were collected and analyzed at 7, 14, and 21 days for expression of 
alkaline phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN), and Runx2 
mRNA levels with real-time RT-PCR.  RNA isolation and quantitative PCR methods are 
detailed in Chapter 3.  Cell number was assessed using the Pico Green® dsDNA 
Quantitation Kit (Molecular Probes) at days 7, 14, and 21 as described previously in 
Chapter 3.  Cell layers were also analyzed for matrix mineralization with the Von Kossa 
staining technique, also described in Chapter 3, for phosphate deposits at day 21.   
4.3.3  Incorporation of heparin into lyophilized collagen matrix 
Synthetic polycaprolactone (PCL) scaffolds (Osteopore, Singapore) were cut from 
a lattice sheet using a biopsy punch (Miltex, York, PA, USA) and incubated in 5 M 
NaOH for 8 hours at 37°C to increase the surface roughness of the polymer.  Scaffolds 
were rinsed twice in DI H2O and sterilized by 70% ethanol evaporation overnight in a 
laminar flow hood.  Type I rat tail collagen (Vitrogen, Palo Alto, CA, USA) was mixed 
with low molecular weight heparin (Sigma,) and lyophilized into the pore space of the 
PCL scaffolds.  Briefly, 100 parts collagen/heparin (1.4 mg/ml collagen + 10 µg/ml 
heparin) in 0.05% acetic acid was combined with 9 parts sodium bicarbonate (71.2 mg/ml 
in DI H2O).  One hundred microliters of the solution was deposited on each scaffold and 
allowed to polymerize at room temperature for 30 minutes.  The scaffolds were then 
transferred to a -80°C freezer for 60 minutes and then lypophilized overnight (Labconco, 
Kansas City, MO, USA) (Figure 4.2). 
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Figure 4.2 Micro-CT image of synthetic polycaprolactone (PCL) scaffold with SEM 
images of lyophilized type I rat tail collagen matrix 
4.3.4 Fluorescently labeled BMP-2 and heparin on collagen matrices 
 BMP-2 was labeled with fluorescein isothiocyanate (FITC) using a Pierce® FITC 
antibody labeling kit (Thermo Scientific, Rockford, IL, USA).  Briefly, the BMP-2 was 
resuspended in an amine-free borate buffer at pH 8-9.  The FITC molecule suspended in 
the labeling reagent crosslinked to primary and secondary amines on the protein and 
excess, un-conjugated FITC molecules were separated from the labeled protein in 
purification resin and spin columns.    
 Labeled protein was then added to collagen or collagen/heparin matrices at a 
concentration of 5µg/ml (0.5 µg/construct).  For comparison BMP-2 pre-incubated with 
heparin (10 µg/ml) was added to collagen matrices.  The fluorescent protein on the 
matrices was imaged and quantified using a confocal laser scanning microscope (CLSM) 
Zeiss 510 with a 488 nm emitting laser (Carl Zeiss, Inc., Thornwood, NY, USA).  See 
Appendix C for detailed confocal image quantification protocol. 
4.3.5 hMSC culture on 3D heparinzed collagen matrix 
 hMSCs were subcultured for 1 week at a low density (500 cells/cm2) and not 
allowed to expand past 70% confluency.  The hMSCs were then trypsinized, counted, and 
seeded on collagen or collagen/heparin scaffolds, with or without 0.5 µg BMP-2.  One 
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million cells were suspended in cell culture media and deposited on each scaffold in a 12-
well plate (Nunc, low cell binding surface).  Cells were allowed to attach to the scaffold 
for 1 hour prior to adding cell culture media, supplemented with 6 mM ß-
glycerophosphate and 50 µg/ml ascorbic acid 2-phosphate, to each well.  Acellular 
controls were prepared by adding 100 µl of cell culture media to the scaffolds and 
subsequently cultured in the same way as the cellular samples.  After 48 hours constructs 
were incubated on a rocker plate to enhance perfusion of nutrients into the center of the 
scaffold.  Consistent scaffold orientation while on the rocker plate was maintained by 
placing the constructs in a holder consisting of sterile ¾” Teflon disks in the 12-well 
tissue culture dish [178]. 
 Cell-seeded scaffolds were harvested at 2 and 5 days post-seeding, rinsed with 
phosphate buffered saline (PBS), and incubated in 4 µM calcein-AM and 4 µM ethidium 
homodimer-1 (Molecular Probes) in PBS for 45 minutes under gentle agitation.  Cell 
viability in the constructs was then assessed with a Zeiss LSM 510 confocal microscope 
(Carl Zeiss, Inc.) through a 10x objective lens.  
 After 3 and 5 weeks in culture, the constructs were removed from cell culture 
media and inserted into a sterile polycarbonate chamber for micro-CT analysis as 
previously described by Porter, et al. [177, 179].  In vitro mineralization was quantified 
using a Scanco Medical Viva-CT scanner (Basserdorf, Switzerland).  Samples were 
evaluated at a global threshold of 78, filter width of 1.2, and filter support of 2.  The 
mineralized matrix volume was determined for each sample.  After imaging, samples 
were removed from the sterile polycarbonate chamber and returned to the Teflon 
construct holders for further culturing. 
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4.3.6 Statistical analysis 
 All data are presented as the mean ± standard error of the mean (SEM), unless 
otherwise stated.  Statistical comparisons using Prism 5 software (GraphPad Software, 
Inc., San Diego, CA, USA) were based on an ANOVA and Tukey’s post hoc analysis for 
pairwise comparison of three or more groups within each time point and p-value < 0.05 
was considered statistically significant.  Other statistical analyses used are stated in the 
results.  When required, raw data was transformed using a logarithmic transformation to 
make the data normal and the variance independent of the mean [142]. 
4.4 Results 
4.4.1 Effect of heparin on BMP-2 levels in cell culture media and BMP-2 mediated 
osteogenic differentiation 
 Analysis of cell culture media with an ELISA indicated significantly more BMP-2 
remained in the media after 3 days when heparin was present at a concentration of 10 
µg/ml compared to 0 and 2 µg/ml heparin (Figure 4.3).  Less BMP-2 remained present in 
the media when incubated with 20 µg/ml heparin compared to 10 µg/ml heparin, however 
this difference was not significant.  There was a slight detection of BMP-2 without the 
addition of exogenous growth factor to the media due to the growth factor content in the 
serum as well as the endogenous expression of BMP-2 in hMSCs, which has been shown 
previously by Seib, et al. [89].  However, the quantities of exogenous BMP-2 detected 
with the ELISA were significantly higher than when no BMP-2 was added to the media 
(p<0.05).  These results confirm that heparin helps protect BMP-2 from degradation, 
thereby maintaining higher concentrations of BMP-2 in culture for prolonged periods.  
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Based on these results, we chose a heparin concentration of 10 µg/ml for future 
experiments. 
 
Figure 4.3 BMP-2 remaining in cell culture media after 3 days in the presence of heparin 
detected with an ELISA (ANOVA: ★ p<0.05, ✚ p<0.05 compared to no BMP-2 with the 
same heparin concentration). 
The combined osteogenic activity of BMP-2 and heparin was confirmed using in 
vitro cell monolayer assays.  First, gene expression was analyzed at 7, 14, and 21 days 
after addition of heparin (10 µg/ml) and/or BMP-2 (100 ng/ml) to the cell culture media 
for alkaline phosphatase, osteogenic matrix proteins: bone sialoprotein and osteocalcin, 
and Runx2 transcription factor (Figure 4.4).  Alkaline phosphatase was significantly 
increased compared to the control by heparin, BMP-2, and the combination of both BMP-
2 and heparin at day 14.  Bone sialoprotein was also significantly increased in the 
presence of the BMP-2 and heparin combination at day 14.  Early changes in osteocalcin 
expression were induced by the combination of BMP-2 and heparin, compared to the 
control at day 7.  Both BMP-2 and the BMP-2/heparin complex significantly increased 
Runx2 expression compared to the control and heparin groups at day 14. 
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Figure 4.4 Osteogenic gene expression in response to BMP-2 and heparin was assessed 
by real time RT-PCR analysis of osteoblastic markers including alkaline phosphatase 
(ALP), bone sialoprotein (BSP), osteocalcin (OCN), and Runx2; (plotted on logarithmic 
y-axes; ANOVA:  p<0.05 versus control,  p<0.05 versus heparin). 
The effect of BMP-2 and heparin on variations in cell number was assessed at days 
7, 14, and 21 with the Pico Green DNA assay (Figure 4.5).  The results indicate that all 
groups experienced a significant increase in DNA content between days 14 and 21 
(p<0.001).  However, hMSCs incubated with BMP-2 had significantly less cells at day 21 
than all other groups, suggesting that BMP-2 without heparin causes a decrease in the 
proliferation rate.   
Matrix mineralization was confirmed by von Kossa staining for phosphate deposits 
in hMSC monolayers after 21 days.  Staining demonstrated that phosphate deposition was 
enhanced when cells were culture in the presence of both BMP-2 and heparin (Figure 
4.6).  A small number of mineralized regions were observed in control and heparin 
treated cell layers.  Interestingly, cell layers cultured with BMP-2 exhibited a small 
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amount of phosphate deposition.  Microscope images of these cell layers showed 
substantial amounts of phosphate nodules in the BMP-2/heparin group, indicating 
osteogenic differentiation of the hMSCs. 
 
Figure 4.5 Effect of BMP-2 and heparin on hMSC number.   DNA was quantified using 
the Pico Green assay (ANOVA: ★ p<0.05 compared to all groups at the same time 
point). 
 
Figure 4.6 von Kossa stain on hMSC layers treated with BMP-2 (100 ng/ml) and/or 
heparin (10 µg/ml) at day 21.  Scale bars = 200µm. 
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4.4.2 Incorporation of heparin in a lyophilized collagen matrix 
 Heparin was incorporated within a lyophilized type I collagen matrix on PCL 
scaffolds.  PCL scaffolds were selected due to their widespread use in tissue engineering 
applications and the structural properties necessary during bone regeneration.  Heparin 
content within the collagen matrix was confirmed with DMMB dye for sGAG content 
(Figure 4.7A).  BMP-2 was added to scaffolds and incubated for 1 hour before adding 
PBS to wells to measure the release kinetics.  A burst release of almost 75% of the initial 
BMP-2 was measured from the collagen scaffolds within the first day and nearly 100% 
was released by two weeks (Figure 4.7B).  Additionally, large variations in BMP-2 
released from collagen scaffolds were observed, with each scaffold releasing at different 
rates.  Conversely, the release of BMP-2 from collagen/heparin scaffolds did not 
experience a large burst release and the kinetics among samples had very little variation.  
Less than 50% of the initial BMP-2 was released from the collagen/heparin scaffolds by 
two weeks, suggesting that most of the BMP-2 was retained within the matrix. 
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Figure 4.7 Incorporation of heparin in a lyophilized collagen matrix.  (A) Heparin 
content confirmed by DMMB dye on PCL scaffolds with lyophilized collagen matrices 
(scaffold dimensions: ø 6 mm x 4.5 mm); (B) BMP-2 release kinetics from collagen and 
collagen/heparin matrices in PCL scaffolds measured by an ELISA. 
4.4.3 Quantification of fluorescently labeled BMP-2 and heparin 
 BMP-2 was labeled with FITC in order to quantify and image the spatial 
distribution of BMP-2 within the scaffolds.  A detailed protocol for quantification of 
fluorescently labeled proteins using confocal microscopy is described in Appendix D.  In 
order to confirm that the collagen and collagen/heparin matrices did not interfere with the 
FITC fluorescent signal, scaffolds without FITC BMP-2 were imaged and compared to 
scaffolds with FITC BMP-2 (Figure 4.8A).   Quantification of the fluorescent area and 
mean intensities in the confocal images indicated that the fluorescent signal was 
significantly greater in samples containing FITC BMP-2 compared to the non-FITC 
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controls (Figure 4.8B and C).  The mean fluorescent intensity measurement was more 
sensitive to the presence or absence of FITC BMP-2 (p<0.001 compared to non-FITC 
control for each matrix type). 
A major advantage of the confocal microscope is the ability to collect accurate 
measurements of fluorescent signals within thick specimens.  We demonstrated the 
capability of the confocal microscope for optical sectioning of the three-dimensional 
collagen and collagen/heparin matrices at different depths within the construct to 
compare the overall spatial distribution of BMP-2 (Figure 4.9A and B).  The FITC-
labeled BMP-2 was observed to be more evenly distributed throughout the 
collagen/heparin matrices compared to the collagen matrix, indicating that BMP-2 binds 




Figure 4.8 Collagen and collagen/heparin matrices do no interfere with FITC BMP-2 
fluorescent signals.  (A) Confocal laser scanning microscope images of control samples 
without FITC and samples with FITC BMP-2 on collagen and collagen/heparin matrices 
(scale bar = 200 µm, applies to all images).  (B) Quantification of fluorescent intensity 
areas of control scaffolds without FITC BMP-2 compared to scaffolds with FITC BMP-2 
(C) Mean fluorescent intensity of scaffolds with and without FITC BMP-2.  (D) BMP-2 
concentrations on collagen or collagen/heparin 3D matrices calculated from the standard 
curve obtained previously, correlating fluorescent intensity area to BMP-2 concentration.  
Dotted line indicates the concentration of the original loading solution (5 µg/ml). (n = 4, 
each sample averaged over 30 image slices; t-test: ★ p<0.05 and ★★ p<0.001 compared 
to non-FITC control) 
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Figure 4.9 Representative confocal image slices along the z-axis for (A) collagen matrix 
with FITC BMP-2, and (B) collagen/heparin matrix with FITC BMP-2.  Scale bars = 100 
µm. 
 
Figure 4.10 Patterns of fluorescent intensity along the z-axis for (A) collagen matrix with 
FITC BMP-2, and (B) collagen/heparin matrix with FITC BMP-2.  Each line represents a 
different sample. 
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 Heparin concentrations within the collagen matrix were then varied to determine 
the effect of heparin content on BMP-2 retention within the matrix (Figure 4.11A and 
B).  The highest concentration of heparin (20 µg/ml) seemed to abrogate the binding 
effects of BMP-2 and heparin, and had BMP-2 levels similar to the collagen matrices 
without heparin.  Still, the lower heparin concentrations (0-10 µg/ml) followed a trend of 
BMP-2 content increasing with heparin concentration. Generally, it is presumed that the 
fluorescent intensity is directly proportional to the amount of fluorescence present.  
However, we saw that although the fluorescent area was different among the varying 
heparin concentrations, the fluorescent intensity did not demonstrate any differences.  
This indicates that fluorescent intensity measurements are not highly sensitive to changes 
in the concentration of fluorescence present; rather it mainly detects the overall presence 
or lack of fluorescent signals and not gradients of fluorescent signals. 
 
Figure 4.11 BMP-2 content on collagen matrices is influenced by heparin concentration. 
Quantification of fluorescent intensity area of FITC-labeled BMP-2 on lyophilized 
collagen matrices with varying concentrations of heparin (n=4; each sample averaged 
over 30 image slices) 
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Confocal microscopy was then used to assess the capacity of collagen and 
collagen/heparin matrices to retain BMP-2.  Collagen and collagen/heparin scaffolds with 
FITC BMP-2 were imaged before and after a 30-minute wash in PBS on a shaker plate 
(Figure 4.12A).  Image analysis indicated that only about 50% of the BMP-2 remained 
on the collagen matrix after the wash treatment, while nearly 100% of the BMP-2 
remained on the collagen/heparin matrix after the wash treatment (Figure 4.12B and C).  
Both the fluorescent area and mean fluorescent intensity were significantly different 
between pre- and post-wash for the collagen matrices.  The decrease in fluorescent 
intensity further confirms that the decrease in fluorescent area was in fact due to an 




Figure 4.12 Collagen/heparin matrices retain higher amounts of BMP-2.  (A) Confocal 
image slices of FITC-labeled BMP-2 on collagen or collagen/heparin lyophilized 
matrices before and after a 30-minute wash treatment (scale bar = 200µm, applies to all 
images); Quantification of BMP-2 on collagen or collagen/heparin matrices: (B) 
fluorescent area and (C) fluorescent intensity of FITC-labeled BMP-2 on collagen or 
collagen/heparin lyophilized matrices before and after a 30-minute wash treatment.  (n=4, 
each sample averaged from 55-60 image slices; ANOVA: $ p<0.05, # p<0.01 compared 
to pre-wash) 
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Further, in a separate experiment, the retention of pre-complexed BMP-2 and 
heparin was analyzed.  FITC BMP-2 and heparin were pre-bound for 30 minutes prior to 
adding to the collagen matrix.  Confocal imaging showed that the BMP-2/heparin 
complex did not have a significant decrease in BMP-2 content after the 30-minute wash 
(Figure 4.13), as BMP-2 alone on the collagen matrix did previously.  It seems that the 
BMP-2/heparin complex has an interaction to some extent with the collagen matrix even 
when heparin is not directly incorporated into the matrix.  However, the levels of BMP-2 
detected after washing still decreased, unlike the BMP-2 levels previously detected on the 
collagen/heparin matrices. 
 
Figure 4.13 Quantification of the BMP-2/heparin complex on collagen matrix: (A) 
average fluorescent area and (B) mean fluorescent intensity of FITC-labeled BMP-2 pre-
complexed with heparin on collagen lyophilized matrices before and after a 30-minute 
wash treatment.  (n=4, each sample averaged from 55-60 image slices; groups compared 
with paired t-test) 
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4.4.4 Effect of heparin in lyophilized collagen matrix on BMP-2 mediated differentiation 
of hMSCs in 3D in vitro culture 
 One million hMSCs were seeded on collagen and collagen/heparin matrices with or 
without BMP-2 and cultured in vitro under static conditions.  Cell attachment and 
viability were assessed after 2 and 5 days using live/dead staining and confocal 
microscopy.  After 2 days in culture, live/dead staining showed that matrix composition 
did not have a major effect on cell adhesion, distribution, or morphology (Figure 4.14).  
However, differences in cell localization were observed among scaffolds with or without 
BMP-2, with cells located largely on the struts when BMP-2 was present.  However, by 5 
days cells on all matrix types with or without BMP-2 filled the scaffolds.  The cells on all 
scaffolds were also observed to have high cell viability. 
 
Figure 4.14 Viability of hMSCs in collagen and collagen/heparin matrices.  Cell 
viability, distribution, and morphology were determined with live (green)/dead (red) 
staining of cells seeded on collagen and collagen/heparin scaffolds and imaged on a 
confocal microscope after 2 and 5 days.  Scale bars = 50 µm, applies to all images. 
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BMP-2 mediated mineralization within collagen and collagen/heparin matrices 
was quantified using micro-CT analysis at 3 and 5 weeks (Figure 4.15A and B).  Cells 
on collagen/heparin scaffolds with BMP-2 deposited significantly greater amounts of 
mineral compared to collagen scaffolds with BMP-2 as well as collagen/heparin scaffolds 
without BMP-2.  Mineral deposition was also increased on collagen/heparin scaffolds 
with BMP-2 at both 3 and 5 weeks compared to acellular collagen/heparin scaffolds, 
indicating that the mineralization observed was due to cell-mediated matrix deposition 
and not due to precipitation of media components onto the scaffolds.  In contrast, 
collagen matrices with BMP-2 showed no significant increase at either 3 or 5 weeks 
compared to acellular and non-BMP-2 groups.  Collagen matrices with the pre-bound 
BMP-2/heparin complex had less mineral formation than collagen/heparin + BMP-2 




Figure 4.15 BMP-2 mediated mineralization capacity of hMSCs on collagen or 
collagen/heparin matrices.  (A) Representative micro-CT images of hMSCs seeded on 
collagen and collagen/heparin matrices with or without BMP-2 after 5 weeks in vitro. (B) 
Quantification of mineral volume by micro-CT image analysis after 3 and 5 weeks in 
vitro (ANOVA: p<0.05 ★ compared to collagen/heparin (acellular), # compared to 
collagen/heparin, $ compared to collagen + BMP-2) 
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4.5 Discussion 
The use of BMP-2 in tissue engineering has exhibited potential for bone 
regeneration, however is largely limited by the short half-life due to degradation and 
rapid diffusion from the implant site.  In Specific Aim I we showed that the sustained 
delivery of BMP-2 from a lipid microtube system did not provide a significant benefit for 
hMSC mineralization compared to a bolus dose of BMP-2.  In this study, we investigated 
the incorporation of heparin in a collagen matrix in order to improve the retention and 
bioactivity of BMP-2.  We showed that incorporating heparin into a collagen matrix 
delivery system delays diffusion of BMP-2 from the scaffold and enhances BMP-2 
mediated mineralization.   
Biomaterials are often modified to improve bioactivity and biocompatibility. 
Incorporating matrix molecules, such as heparin, in the biomaterial closely mimics the 
natural ECM leading to improved retention of many growth factors, including BMP-2. 
Matrix-bound growth factors are temporarily retained in vivo by sGAGs, such as heparin, 
in the ECM protecting the growth factor from proteolytic degradation and delaying 
diffusion into the surrounding tissue [94, 180].  Low molecular weight heparin has 
previously been shown to be a useful molecule in stabilizing the BMP-2 structure as well 
as enhancing the BMP-2 activity [96, 117].  It has also been shown that heparin in the 
ECM sequesters BMP-2 at the cell surface, near the receptors, and mediates 
internalization of the protein, which further mediates BMP-2 activity [180].  This 
matrix/growth factor interaction was employed in this study by incorporating heparin in a 
collagen matrix system to improve the retention and bioactivity of BMP-2.   
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In the presence of heparin, higher levels of BMP-2 were maintained in the cell 
culture media after three days, confirming that the heparin protected the BMP-2 molecule 
from proteolytic degradation as well as thermal denaturing. Zhao et al. previously 
demonstrated this stabilizing effect, where the half-life of BMP-2 was prolonged by 
almost 20-fold in the presence of heparin [96].  The higher levels of BMP-2 remaining in 
the media corresponded with a significant increase in osteogenic differentiation of 
hMSCs, as indicated by increased osteogenic gene expression as well as more phosphate 
deposits detected by Von Kossa staining.  These results support previous work with 
C2C12 myoblasts that indicated heparin enhances the biological activity of BMP-2 [96, 
117].   
We demonstrated that the collagen/heparin matrices delayed the release of BMP-2 
as shown in the release kinetics.  Collagen matrices had highly variable and rapid release 
of BMP-2, with nearly 75% being released within the first day, and almost 100% by 2 
weeks.  Conversely, collagen/heparin matrices released less than 50% of the BMP-2 by 2 
weeks and had very consistent release kinetics across samples.  The variability observed 
in the BMP-2 release kinetics from the collagen matrices could induce significant 
variability during clinical trials, which may result in variable healing responses and side 
effects [6, 83, 90, 97].  Uludag, et al. has previously shown that BMP-2 releases rapidly 
from collagen sponges implanted in an ectopic site, in which approximately 60% of the 
initial BMP-2 remained three hours after implantation and less than 5% remained in the 
sponges two weeks after implantation [158].  They later demonstrated that improved 
BMP-2 retention within the carrier increases bone formation [18].  Therefore, we 
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hypothesized that delivery of BMP-2 in the collagen/heparin matrix would enhance 
mineralization. 
Confocal imaging of FITC-labeled BMP-2 also demonstrated that collagen 
matrices had poor retention of BMP-2 after a 30-minute wash treatment.  BMP-2 
concentrations remained the same after washing when heparin was incorporated in the 
collagen matrix.  Further, when BMP-2 and heparin were pre-bound prior to adding to a 
collagen matrix, retention was not as good as observed in the collagen/heparin matrix.  
However, the decrease in BMP-2 content was not as drastic on the collagen matrix when 
BMP-2 and heparin were pre-complexed.  This effect may be due to the larger size of the 
BMP-2/heparin complex compared to BMP-2 alone, thus reducing the diffusion from the 
collagen matrix [111].  Additionally, this effect may be caused by the inherent 
interactions of heparin with other ECM components, thereby causing the BMP-2/heparin 
complex to have an affinity for the collagen matrix [31].  However, this affinity of the 
BMP-2/heparin complex with collagen does not improve the BMP-2 retention as much as 
incorporating the heparin within the matrix.  Release of BMP-2 from these systems can 
happen as a result of various events including the dissociation of BMP-2 from the matrix 
molecules, diffusion of the matrix molecules, or degradation of the matrix.  Similar to our 
study, Visser, et al. demonstrated that BMP-2 had poor retention in collagen sponges 
after a wash treatment, unless the system was altered to improve binding of BMP-2 to 
collagen [21].   
We also demonstrated that high concentrations of heparin (20 µg/ml) reversed the 
effects of heparin on BMP-2 binding and stability.  Analysis of the cell culture media 
samples after 3 days showed that the high dose of heparin had no added effect on 
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remaining BMP-2 over 10 µg/ml heparin, and had BMP-2 concentrations similar to 
samples without any heparin.  Moreover, confocal imaging of the 3D collagen/heparin 
scaffolds indicated that 20 µg/ml heparin did not enhance binding of BMP-2 to the matrix 
over 10 µg/ml heparin, and again had BMP-2 concentrations similar to the collagen 
matrix without heparin.  Similarly, high heparin concentrations have previously been 
shown to inhibit growth factor activity, as well as reduce cell number and matrix 
deposition [181, 182].  This effect has been attributed to multiple causes, such as non-
specific competition with endogenous sGAGs, however no clear reason has been 
determined for this inhibitory activity.  Other studies have demonstrated use of heparin to 
protein molar ratios between 1:25 and 1:500, and showed that a moderate ratio of protein 
to heparin was most beneficial for bioactivity [111].  Our results in combination with the 
previous work indicate that lower heparin concentrations will be beneficial for BMP-2 
delivery. 
Cell attachment and morphology on scaffolds are key factors when evaluating cell 
proliferation and differentiation.  Previous work has shown that immobilized growth 
factors cause changes in cell attachment and morphology, which is critical for cell 
differentiation [174, 183].  Our results clearly demonstrated that there were no 
differences in cell attachment, morphology, or growth on collagen or collagen/heparin 
matrices when BMP-2 was present.  However, the consistent presence of BMP-2 within 
the collagen/heparin matrix resulted in a significant increase in BMP-2 mediated 
mineralization of hMSCs.  The differences in mineralization may be due to the quick 
diffusion of BMP-2 from the collagen matrices, before the cells reached confluency and 
were able to begin differentiating.  We showed by live/dead staining that the cells are not 
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confluent immediately after seeding, and required more than two days to fully populate 
the scaffold.  Seib, et al. showed that MSCs require higher cell densities (>10, 000 
cells/cm2) for significant osteogenic differentiation [89].  Therefore, osteoinductive 
factors need to be present when the cells have reached this state in order to induce 
osteogenic differentiation.  The collagen/heparin matrices retained the BMP-2 for longer 
periods of time, ensuring that the growth factor was still present when the hMSCs 
reached confluency and were able to begin differentiating.  Acellular collagen/heparin 
matrices did not exhibit any mineral deposition, indicating that the mineral formation 
observed in other groups was due to cell-mediated mineral deposition and not the 
precipitation of media components.  Similarly, Peister, et al. demonstrated that no 
mineralization occurred in acellular collagen matrices [178]. 
Other biomaterial approaches for growth factor delivery have directly linked 
either the proteins or the heparin to the material through chemical reactions that create 
covalent bonds between the molecule and the biomaterial [26, 173, 174, 184]. However, 
direct surface coupling of proteins and the biomaterial often result in drastic 
conformational changes in the protein, which can compromise the protein activity and 
may cause an adverse response in vivo due to the foreign protein structure [185].  
Conformational changes may also affect the binding affinity of proteins with their 
receptors or other molecules, resulting in suboptimal activity [29, 183].  Osmond, et al. 
showed that different methods for chemical immobilization of heparin affected the 
binding capacity of heparin and a protein [29].  The work in this Aim is beneficial 
because the collagen/heparin system utilizes no chemical alterations to the heparin or 
BMP-2 in order to improve retention.  
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4.6 Conclusions 
In this study, we developed an affinity-based delivery system to retain BMP-2 
within bone tissue engineering constructs.  We utilized the binding properties of BMP-2 
and heparin to delay diffusion of the growth factor from the scaffold.  The results 
demonstrated that heparin incorporation into collagen matrices improves BMP-2 
retention and delays the release.  Subsequently, BMP-2 mediated differentiation of 
hMSCs was significantly enhanced when heparin was incorporated in the collagen 
matrix.  These results suggest that the collagen/heparin matrix delivery system may be 
beneficial as a bone tissue engineering therapy.  In Specific Aim III we assess the 





EVALUATION OF A BMP-2 DELIVERY SYSTEM IN AN IN VIVO 
SEGMENTAL DEFECT MODEL 
 
5.1 Abstract 
 The collagen/heparin delivery system developed in Chapter 4 was quantitatively 
evaluated in vivo using a previously developed critically-sized rat segmental defect 
model.  BMP-2 was delivered in the collagen or collagen/heparin matrices on PCL 
scaffolds promote bone regeneration within the critically-sized defects.  A group 
delivering pre-complexed BMP-2/heparin in a collagen matrix was also included for 
comparison.  A previously developed fixation design was used to consistently stabilize 
the defect as well as provide an imaging window for longitudinal in vivo two-dimensional 
x-ray and three-dimensional micro-CT analysis of bone formation.  After 12 weeks, the 
femurs were explanted and analyzed for functional bone regeneration with torsional 
mechanical testing.  Sequential in vivo micro-CT imaging demonstrated that there was 
significantly more mineralized tissue within the defect site when treated with BMP-2.  
Post-mortem analyses showed that only the pre-complexed BMP-2/heparin delivered in 
the collagen matrix restored mechanical properties to levels near age-matched intact 
femurs.  The in vitro micro-CT analyses demonstrated that the mineralized tissue was 
more organized when pre-complexed BMP-2/heparin was delivered to the defect, 
indicating mature bone formation.  The results from this study indicate that the co-
delivery of BMP-2 and heparin may be a potential therapy for defect repair. 
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5.2 Introduction 
Although structural allografts are currently the standard treatment for bone 
defects, these treatments experience unacceptably high rates of failure due to incomplete 
revascularization and bone remodeling.  Tissue engineering therapies that include growth 
factors, such as BMP-2, provide a possible alternative to bone graft substitutes.  BMPs 
were originally identified as molecules that could induce ectopic bone formation when 
implanted in subcutaneous or intramuscular sites, classifying them as osteoinductive 
proteins.  Thus, the in vivo rodent subcutaneous or intramuscular ectopic implantation 
assay is the standard model to demonstrate BMP-2 activity in initiating and maintaining 
the bone formation cascade [17, 106, 186].   However, the ectopic assay does not provide 
a clinically relevant in vivo model for fracture healing.  A segmental defect model will be 
utilized in this study to assess the performance of the BMP-2 delivery system developed 
in Specific Aim II for fracture healing applications. 
Many in vitro models and assays have been developed to examine BMP-2 
mediated osteogenesis, however these methods are oversimplified and do not account for 
systemic factors, thus still requiring validation in vivo. The in vivo ectopic implantation 
model has been the standard assay for evaluating BMP-2 activity; nevertheless it does not 
serve as a clinically relevant model.  Therefore, other research has tried to assess the 
efficiency of BMP-2 in healing critically-sized defects in rat, rabbit, sheep, and dog 
models [83, 84, 187, 188].  However, the necessary dose for fracture healing exceeds the 
therapeutic window and may result in severe adverse effects.  One approach to address 
growth factor dosing issues has been to deliver genetically modified cells to over-express 
the desired growth factor [74, 105].  These approaches are often controversial due to the 
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viral vectors necessary to genetically modify the cells [7].  Other approaches for growth 
factor therapies have included sustained delivery and affinity-based systems [17, 22].  
The delivery of growth factors in materials that promote the growth factor activity while 
also delaying protein denaturing in vivo may result in enhanced bone formation at lower 
doses. 
BMP-2 activity in vivo is largely mediated by transiently binding to 
glycosaminoglycans (GAGs), such as heparin, in the bone extracellular matrix (ECM).  
Thus, heparin has been incorporated into BMP-2 delivery systems to improve the affinity 
and release properties [17, 20, 115].   These delivery systems have been evaluated in vivo 
to assess improvement in bioactivity and retention of BMP-2 for bone regeneration 
therapies.  In 2008, von Walter, et al. reported the benefit of a heparinized collagen 
system for the delivery of BMP-2 in a rabbit bone defect model, in which a cylindrical 
defect was created laterally in the femoral condyle [20].  Other studies have used 
subcutaneous and intramuscular implantation models to demonstrate the improved ability 
of BMP-2 to induce ectopic bone formation when delivered with heparin [17, 96, 186].  
However, the ectopic assays simply assess matrix mineralization and not bone repair.  
The potential of heparin-binding delivery systems have not yet been evaluated in a 
segmental femoral defect, which provides a clinically relevant and robust test bed for 
evaluating bone repair. 
The standard rat segmental defect model was modified to an 8 mm defect 
dimension in order to achieve a stable fixation of a critically-sized defect, while also 
allowing in vivo micro-CT and X-ray imaging [82, 189, 190].  This model is highly 
reproducible and utilizes a large, stable defect for evaluation of tissue engineering 
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strategies for load-bearing situations.  The majority of segmental defect animal models 
utilize qualitative radiographic analyses and end-point histological methods to evaluate 
healing.  However, more quantitative measures of functional, integrated bone healing is 
necessary to thoroughly evaluate bone tissue engineering strategies.  Micro-CT based 
methods have been established to quantify the 3D distribution of mineralized matrix 
growth into the defect [82, 191, 192].  Biomechanical testing has also been used to 
evaluate the restoration of bone function [82, 192, 193]. 
In Specific Aim II (Chapter 4) we showed that collagen/heparin matrix retained 
BMP-2 longer and improved BMP-2 mediated mineralization in vitro.  The purpose of 
this aim was to test the BMP-2 delivery system developed in Aim II in a challenging and 
clinically relevant in vivo model in order to determine the potential of this delivery 
system to induce new bone formation.  The hypothesis was that the collagen/heparin 
matrix would improve BMP-2 retention in vivo compared to delivery in a collagen 
matrix, thereby enhancing bone regeneration.  
5.3 Methods and Materials 
5.3.1 Collagen/heparin matrix for the delivery of BMP-2 
 Nine millimeter thick PCL scaffolds (Osteopore, Singapore) were cut from a lattice 
sheet using a 5 mm biopsy punch (Miltex, York, PA) and incubated in 5M NaOH for 8 
hours at 37°C to prepare the polymer surface for matrix incorporation.  Scaffolds were 
rinsed twice in deionized H2O and sterilized by 70% ethanol evaporation overnight in a 
laminar flow hood.  Type I rat tail collagen (Vitrogen, Palo Alto, CA) was mixed with 
low molecular weight heparin (porcine intestinal mucosa; Sigma) and lyophilized into the 
pore space of the PCL scaffolds as described in Chapter 4.  Two hundred microliters of 
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the collagen solution was deposited on each scaffold and allowed to gel at room 
temperature for 30 minutes.  The scaffolds were then transferred to -80°C for 60 minutes 
and then lypophilized overnight (Labconco, Kansas City, MO).  
 A volume of 175 µl containing 3 µg of rhBMP-2 (carrier free, CHO-derived, R&D 
Systems, Minneapolis, MN, USA) was pipetted onto the collagen matrices at least 30 
minutes prior to implanting into the defect.  BMP-2 was also pre-incubated with 10 µg/ml 
heparin for 30 minutes prior to adding to the collagen scaffold. 
5.3.2 Surgical technique 
 All surgical procedures were reviewed and approved by the Institutional Animal 
Care and Use Committee (IACUC) at the Georgia Institute of Technology (Protocol 
#A08032).  The surgical technique and analysis previously described by Oest, et al. was 
used [82].  Female Sasco Sprague-Dawley rats (Charles River Labs, Wilmington, MA) 
aged 13 weeks were anesthetized with isoflurane and bilateral incisions were made along 
the length of the hind limbs.  A modular fixation plate consisting of a polysulfone plate 
and two stainless steel plates was directly secured to the femur using four miniature 
screws (Figure 5.1).  Bilateral full-thickness diaphyseal segmental defects, 8 mm in 
length, were created using a small oscillating saw and flushed with saline.  Defects were 
filled with PCL scaffolds containing one of the following treatments: collagen matrix 
(n=5), collagen/heparin matrix (n=7), collagen matrix + BMP-2 (n=9), collagen/heparin 
matrix + BMP-2 (n=9), and collagen matrix + BMP-2/heparin complex (n=9).  All groups 
receiving BMP-2 had a dose of 3 µg.  Animals received 0.05 mg/kg buprenorphine 
subcutaneously every 12 hours for the first 48 hours post-op.  Within 2-3 days post-op, 
the animals resumed normal ambulation and showed no signs of pain or distress. 
 88 
 
Figure 5.1 Rat femur with 8 mm defect and fixation plate assembly 
5.3.3 2D X-ray and 3D Micro-CT imaging 
 In vivo digital x-rays (Faxitron MX-20 Digital; Faxitron X-ray Corp., Wheeling, IL) 
were obtained at 2, 4, 8, and 12 weeks post-op to provide a two-dimensional qualitative 
assessment of healing and defect stability over time.  The radiolucent properties of the 
polysulfone fixation plate allowed for clear imaging of the defect.  Qualitative assessment 
of bone regeneration was determined by two blinded observers and classified according 
to the extent of defect bridging. 
 Quantitative 3D analysis of bone regeneration in the defects was performed at 4, 8, 
and 12 weeks post-op using an in vivo micro-CT system (Viva-CT 40; Scanco Medical, 
Bassersdorf, Switzerland) following the technique described by Oest, et al. [82].  The 
defect region was scanned at a 38.5 µm voxel resolution, a voltage of 55 kVp and a 
current of 109 µA.  A constant volume of interest (VOI) centered over the defect site was 
used for analysis of all samples (100 slices thick for in vivo scans and 300 slices thick for 
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in vitro scans).  A Guassian filter (sigma = 1.2, support = 1) was used to reduce noise 
levels in the VOI prior to applying a global threshold.  Appropriate threshold levels for in 
vivo and in vitro scans were determined by examining individual slices to detect newly 
formed mineralized tissue and to exclude soft tissue, the PCL scaffold, and the 
polysulfone plate. 
5.3.4 Mechanical Testing 
 Animals were euthanized at 12 weeks post-op and samples were harvested and 
wrapped in saline-soaked gauze for storage at -20°C.  Thawed samples were subjected to 
torsion testing immediately after in vitro micro-CT scanning, using a Bose ElectroForce 
system (ELF 3200, Bose EnduraTEC, Minnetonka, MN) with a 2 N-m torsional load cell.  
First, the femur ends were embedded in end blocks using Wood’s metal (Alfa Aesar, 
Ward Hill, MA) and pinned through the potting blocks for extra stability in the end 
blocks.  The polysulfone fixation plates were removed without disrupting the defect and 
the samples were tested at a rate of 3°/s to failure.  Torque and rotation were recorded and 
exported for analysis.   Unbridged samples displayed a gradual increase in torque and did 
not experience an abrupt failure point due to stretching of the soft tissue.  For these 
samples the failure torque was measured in the first 60° in order to exclude the forces 
generated due to soft tissue deformation.  Stiffness was calculated by determining the 
slope of a straight line fitted to the linear portion of the torque-rotation plot prior to 
failure.   
5.3.5 Statistical analysis 
 All data are presented is the mean ± standard error of the mean (SEM), unless 
otherwise stated.  When necessary, raw data was transformed using the Box-Cox method 
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to make the data normal and the variance independent of the mean [194].  Statistical 
comparisons using Minitab® 15 software (MiniTab Software, Inc., San Diego, CA, USA) 
were based on an ANOVA using a general linear model and Tukey’s post hoc analysis 
for pair-wise comparison of three or more groups.  Differences were considered 
statistically significant for p < 0.05 and a trend for p < 0.10.  
5.4 Results 
 During the course of the study one animal was euthanized 48 hours post-op due to 
rapid weight loss and minimal activity, indicating pain or distress.  Another animal was 
euthanized at 7 weeks post-op due to bacterial infections in both limbs, which caused 
substantial necrosis of the surrounding tissue.   
5.4.1  Qualitative analysis of digital x-ray images 
Digital two-dimensional x-ray images were used to qualitatively assess the 
progression of bone regeneration into the defect (Figure 5.2).  In non-BMP-2 controls, 
there was a minimal amount of bone formation observed in the defects throughout the 
study.  Conversely, x-ray images of groups with BMP-2 or BMP-2/heparin demonstrated 
bone regeneration in the defects.  Collagen + BMP-2/heparin appeared to have more 
mineralized tissue at 2 weeks than other groups, with one defect already demonstrating 
full bridging and four more defects with a substantial amount of bone formation (Table 
5.1).  The collagen + BMP-2 group also had one defect fully bridged by two weeks, but 
the majority of the defects in this group still had minimal bone formation at this time 
point.  By 4 weeks, all groups treated with BMP-2 had similar bridging rates.  At both 
eight and twelve weeks post-op, about 60% (15 of 25) of the defects treated with BMP-2 
had complete bridging compared to only 9% (1 of 11) of the non-BMP-2 groups.  Chi-
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square (χ2) analysis of the ratios revealed that the bridging rates between all groups was 
not significantly different (p=0.065), but were significantly different when comparing 
groups treated with BMP-2 to the non-BMP-2 controls (p=0.0046).  Moreover, 
disconnected areas of bone formation occurred outside the defect region when treated 
with collagen + BMP-2 scaffolds, indicating diffusion of BMP-2 out of the scaffold.  
Defects treated with collagen/heparin + BMP-2 or collagen + BMP-2/heparin scaffolds 
appeared to have more localized bone formation. 
 92 
Table 5.1 Bridging rates assessed from 2D x-ray images 
Group 2 weeks 4 weeks 8 weeks 12 weeks 
Collagen 0/5 0/5 0/5 0/5 
Collagen/heparin 0/7 0/6 1/6 1/6 
Collagen + BMP-2 1/9 3/9 5/9 5/9 
Collagen/heparin + BMP-2 0/9 4/9 5/9 5/9 
Collagen + BMP-2/heparin 1/8 4/7 5/7 5/7 
 
 
Figure 5.2 Representative in vivo 2D x-ray images of defect sites obtained at 2, 4, 8, and 
12 weeks post-op.   
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5.4.2 In vivo quantitative micro-CT analysis of bone formation  
 Evaluation of in vivo micro-CT scans allows for the quantification of bone 
formation in the defect region within the same animal at multiple time points.  The 
volume of mineralized tissue was quantified within a consistent volume of interest (VOI) 
centrally located within the 8 mm defect at 4, 8, and 12 weeks post-op (Figure 5.3). 
Delivery of BMP-2 and BMP-2/heparin on the collagen matrix significantly increased 
mineral formation at 4 weeks compared to non-BMP-2 controls, and remained 
significantly higher than the collagen only group at 12 weeks (Figure 5.4A). BMP-2 
delivered in the collagen/heparin matrix had slightly lower mineral formation than BMP-
2 and BMP-2/heparin in collagen matrices, however the differences between these groups 
were not significant. Collagen + BMP-2 had the largest increase in volume from 4 to 8 
weeks, significantly higher than both non-BMP-2 control groups.  However, all groups 
produced less new mineral from 8 to 12 weeks, as indicated by the small changes in 
volume within the last 4 weeks of the study (Figure 5.4B).  
Mean density and connectivity density of the regenerated bone was also evaluated 
at 4, 8, and 12 weeks from in vivo micro-CT scans.  Both collagen + BMP-2 and 
collagen/heparin + BMP-2 groups had significantly lower hydroxyapatite densities at 8 
and 12 weeks compared to the collagen only group (Figure 5.5A).  It should be noted 
that this quantity is the actual density of the mineralized tissue and not the apparent 
mineral density of the entire volume.  The bone density significantly increased from week 
4 to week 8 (p<0.001) in all groups indicating maturation of the newly formed 
mineralized tissue.  Between 8 and 12 weeks, all groups containing BMP-2 continued to 
significantly increase in density (p<0.05).  At 4 and 8 weeks, the connectivity density was 
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significantly higher in the collagen + BMP-2 group compared to the collagen only group.  
Additionally, the collagen + BMP-2/heparin group had significantly higher connectivity 
density at 4 weeks compared to collagen and collagen/heparin groups (Figure 5.5B).  




Figure 5.3 Three-dimensional in vivo micro-CT images at 4, 8, and 12 weeks post-op. 
The images were analyzed over a volume of interest (VOI) 100 slices thick that was 
centrally located within the 8 mm defect. 
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Figure 5.4 Quantitative evaluation of in vivo bone formation from micro-CT images at 4, 
8, and 12 weeks post-op.  (A) Volume of mineralized tissue (mm3). (B) Volume change 
of mineralized tissue (mm3) between time points.  # p<0.05 compared to collagen, $ 
p<0.05 compared to collagen/heparin. 
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Figure 5.5 Quantitative evaluation of density and connectivity density from in vivo 
micro-CT images at 4, 8, and 12 weeks post-op.  (A) Mean hydroxyapatite density (mg 
HA/cm3) and (B) Connectivity density (1/mm3) between time points. # p<0.05 compared 
to collagen, $ p<0.05 compared to collagen/heparin. 
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5.4.3 In vitro quantitative micro-CT analysis of bone formation in segmental defect 
 Quantitative micro-CT analysis was performed post-mortem on the explanted 
femurs prior to mechanical testing (Figure 5.6A and B).  Consistent with the 12 week in 
vivo scans, all groups with BMP-2 had significantly more mineralized tissue in the defect 
region than the collagen only group (p<0.05).  The group that received pre-complexed 
BMP-2/heparin in the collagen matrix had the highest volume of mineralized tissue, 
however the differences between the groups with BMP-2 were not significant.  The pre-
complexed BMP-2/heparin group also had the highest connectivity density, indicating a 
more interconnected mineralized structure, although this difference was not significant.  
As expected, the mineralized tissue volume and connectivity density quantities were 
dominated by the contributions from the fully bridged samples, indicating that these 
measures are good assessments of defect healing (Figure 5.6C and D).  Interestingly, the 
differences between connectivity density in bridged and unbridged samples from the 




Figure 5.6 Quantitative evaluation of mineralized tissue volume and connectivity density 
from in vitro micro-CT images of 12 weeks post-mortem samples: (A) Volume of 
mineralized tissue (mm3) and (B) Connectivity density (1/mm3). (C) Contributions of 
unbridged and bridged samples to mineralized tissue volume.  (D) Contributions of 
unbridged and bridged samples to connectivity density.  (# p<0.05 compared to collagen) 
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5.4.4 Post-mortem mechanical testing 
 Torsional testing was performed on explanted samples at 12 weeks post-op to 
determine the functional integration of the regenerated bone.  A plot of torque versus 
angular displacement was generated for each sample in order to calculate the maximum 
torque and stiffness.  Defects treated with BMP-2/heparin on the collagen matrix had the 
highest strengths, reaching an average maximum torque of 0.204 ± 0.079 N-m (mean ± 
SEM), which was only slightly below the torsional strength of age-matched intact bones 
(0.31 ± 0.016 N-m [189, 195]), and the only group that was not significantly different 
from intact bone.  The maximum torque for this group (collagen + BMP-2/heparin) was 
significantly greater than both non-BMP controls (collagen and collagen/heparin).  
Defects treated with BMP-2 on either the collagen or collagen/heparin matrix had lower 
maximum torques of 0.053 ± 0.023 and 0.079 ± 0.047 N-m, respectively (Figure 5.7A).  
The collagen/heparin + BMP-2 group was significantly greater than only the collagen 
group.  The collagen + BMP-2 was not significantly greater than either non-BMP control 
group.  Upon further consideration of the results for maximum torque we noted that a 
majority of the torsional strength could be attributed to the bridged samples, and the 
unbridged samples demonstrated the torsion curve patterns of soft tissue and polymer 
material (Figure 5.7C).  The maximum torque of bridged samples in the collagen+BMP-
2/heparin group was not significantly different than that of intact bone.  When only the 
bridged samples were compared, the intact bone was significantly different from the 
collagen+BMP-2 group.   
Similar trends were observed in the torsional stiffness. Control groups (collagen 
and collagen/heparin without BMP-2) had minimal resistance to the torsional 
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deformation induced (Figure 5.7B).  Defects treated with BMP-2/heparin in the collagen 
matrix had the highest stiffness of 0.014 ± 0.006 N-m/deg (mean ± SEM), approximately 
50% of the intact bone stiffness previously measured [189, 195], however this difference 
was not significant.  Intact bone had significantly higher stiffness than the other groups.  
Delivery of BMP-2 in either collagen or collagen/heparin matrices yielded torsional 
stiffness an order of magnitude lower than intact bone (0.005 ± 0.002 and 0.0043 ± 0.003 
N-m/deg, respectively).   Additionally, we observed that the bridged samples contributed 
the majority of torsional stiffness, yet the collagen+BMP-2 and collagen/heparin+BMP-2 
bridged samples were still significantly lower than intact bone (Figure 5.7D).   
Although all groups delivering BMP-2 had similar volumes of bone formation, 
only delivery of BMP-2/heparin in the collagen matrix was able to restore mechanical 
properties to levels similar to those of intact bone.  Therefore, in order to assess if the 
bone volume and connectivity density had an effect on biomechanical properties, we 
performed linear regression analyses between the variables.  First, we examined bone 
volume in relation to maximum torque and stiffness (Figure 5.8, Table 5.2).  When data 
from all groups were pooled together for analyses, the regressions were significant 
(slopes were significantly non-zero) but had weak correlations (low R2 values).  Among 
the bridged samples only, the correlations with maximum torque and stiffness did not 
improve (R2 = 0.56 and 0.52, respectively).  However, when each treatment group was 
analyzed separately, the collagen + BMP-2/heparin group demonstrated a strong 
correlation between volume and maximum torque (R2 = 0.93), as well as between volume 
and stiffness (R2 = 0.92).  Conversely, the bone volumes in the collagen/heparin + BMP-
2 group did not correlate as powerfully to maximum torque and stiffness.  This suggests 
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that although the amount of bone regenerated in this group was similar to the collagen + 
BMP-2/heparin group, the geometry and orientation of that newly formed bone may not 
have provided optimal mechanical stability.   
Analysis of the relationship between the connectivity density and mechanical 
properties demonstrated similar results.  Overall, the pooled data demonstrated significant 
regressions, but the correlations were weak (Figure 5.9, Table 5.3).  Analysis of only the 
bridged samples did not exhibit any improvement in the correlations with maximum 
torque and stiffness (R2 = 0.35 and 0.40, respectively).  Separately, the groups showed 
differences in their correlations between connectivity density and mechanical properties.  
The collagen + BMP-2/heparin group had weaker correlations than observed with the 
volume relationships (R2 = 0.84 and 0.77), however the correlations were still significant.  
The collagen/heparin + BMP-2 group did not exhibit any significant correlation between 
connectivity density and maximum torque and stiffness.   
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Figure 5.7 Evaluation of mechanical properties of 12 weeks post-mortem samples: (A) 
Maximum torque (N-m), (B) Torsional stiffness (N-m/deg), (C) Contributions of 
unbridged and bridged samples to maximum torque, (D) Contributions of unbridged and 
bridged samples to torsional stiffness. ANOVA: # p<0.05 compared to collagen, $ 
p<0.05 compared to collagen/heparin, & p<0.05 compared to collagen+BMP-2, and ★ 




Figure 5.8 Correlations of mineralized tissue volume to mechanical properties: (A & B) 
Linear regression analysis of combined data from all groups (bridged samples highlighted 
in red); (C & D) Linear regression analysis of each treatment group.  Table 5.2 Goodness 
of fit values for linear regression correlating volume to max torque and stiffness; p-values 




Figure 5.9 Correlations of connectivity density to mechanical properties: (A & B) Linear 
regression analysis of combined data from all groups (bridged samples highlighted in 
red); (C & D) Linear regression analysis of each treatment group.  Table 5.3 Goodness 
of fit values for linear regression correlating connectivity density to max torque and 
stiffness; p-values for significantly non-zero slopes (NS = no significance). 
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Analysis of in vitro micro-CT images was able to demonstrate the density 
distribution of the mineralized tissue within the defects (Figure 5.10).  These images 
further validate the mechanical testing results.  The samples with the highest mechanical 
properties were in the collagen + BMP-2/heparin group, which were shown in the density 
maps to have more organized dense tissue distributed around the perimeter in a manner 
similar to native cortical bone.  The defects treated with collagen + BMP-2 or 
collagen/heparin + BMP-2 had disorganized dense tissue; with dense areas occurring in 
the center around the PCL scaffold struts and disconnected from other dense areas.  
 
Figure 5.10 Representative in vitro micro-CT images with corresponding density maps 
(bottom row) sectioned longitudinally.  The color scale at the bottom correlates to the 
attenuation, which corresponds to the tissue density.  Red indicates the higher density 
bone and green indicates lower density bone. 
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5.5 Discussion 
A number of in vivo studies have recently demonstrated the ability of heparinized 
BMP-2 delivery systems to improve retention and bioactivity.   However, these systems 
have mainly been tested in ectopic assays and have not been quantitatively evaluated in a 
more clinically relevant model for assessment of fracture repair.  Von Walter, et al. 
implanted heparinized collagen sponges with BMP-2 in a cylindrical defect in rabbit 
condyles [20].  Other groups have utilized the ectopic bone formation assay to assess the 
efficacy of incorporating heparin into BMP-2 delivery systems [17, 115, 133, 186].  We 
evaluated the delivery system developed in Specific Aim II (Chapter 4) in an in vivo 
segmental defect model to further determine the potential for the collagen/heparin matrix 
to deliver BMP-2 in bone tissue engineering applications.    
The dose delivered in this work was increased to 3 µg BMP-2 due to the increased 
dimensions of the implanted constructs, as well as consideration of previous work 
demonstrating that higher doses are necessary to promote consistent bone regeneration in 
an in vivo segmental defect model [189, 190].  Nevertheless, the dose used in this study 
(0.02 mg/ml) was orders of magnitude lower than the 1.5 mg/ml dose used clinically in 
the InFUSE™ graft system and in the lower range of doses administered (2-20 µg) in 
similar rodent segmental defect studies [127, 187, 196].  
Quantitative micro-CT analysis was performed at 4, 8, and 12 weeks in vivo, as 
well as post-mortem to assess bone ingrowth into the defect region.  Measures included 
mineralized tissue volume, hydroxyapatite density, connectivity density, maximum 
torque, and stiffness.  Collectively, these measurements can demonstrate the extent of 
functional bone regeneration within the defect for a given treatment.  In vivo analyses 
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showed that treatment of defects with BMP-2 resulted in significantly higher amounts of 
bone formation compared to non-BMP-2 controls, however no significant differences 
among the groups treated with BMP-2 were observed.  Further analysis of the femurs 
post-mortem demonstrated that defects treated with collagen + BMP-2/heparin had the 
greatest amount of bone formation within the defect, significantly higher than the 
collagen only group, as well as the highest connectivity density.  Connectivity density is 
defined as the number of connections per unit volume, or the maximum number of 
connections per unit volume that can be broken before failure [197].  It is generally 
understood that native bone is highly connected, however during bone formation and 
fracture healing isolated regions of bone form [197].  Eventually these isolated areas of 
mineralized tissue develop connections and form highly connected bone.  We observed in 
this study that connectivity densities were highest when pre-complexed BMP-2/heparin 
was delivered in the collagen matrix, indicating regeneration of a more interconnected 
bone structure and therefore higher mechanical stability, however these differences were 
not significant. 
The mechanical properties of the femurs were substantially less than those of 
intact bone, with the exception of femurs treated with collagen + BMP-2/heparin.  Both 
maximum torque and stiffness in the collagen + BMP-2/heparin group were not 
significantly different from the properties seen in age-matched intact bone (0.31 N-m and 
0.03 N-m/deg) [189, 195].  The biomechanical properties in this group were also greater 
than values seen in previous studies using PCL scaffolds in the same segmental defect 
model [192].  The higher mechanical properties seen in the collagen + BMP-2/heparin 
may have been attributed to the higher rate of bridging, 71% compared to 56% in both 
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the collagen + BMP-2 and collagen/heparin + BMP-2 groups, however upon analysis of 
the bridged samples the collagen + BMP-2 group remained significantly lower than the 
intact bone.   The collagen + BMP-2/heparin group was also observed to have the highest 
connectivity density, which strongly correlated to the higher biomechanical properties.  
Other groups had weaker correlations between connectivity density and biomechanical 
properties, indicating that the organization of the mineralized matrix in these groups did 
not provide optimal mechanical integrity.  The matrix in these groups may still be 
immature bone and require more time to organize into more mature bone, whereas the 
collagen + BMP-2/heparin may have accelerated defect bridging resulting in more time 
for bone remodeling.  
Previously, we showed in vitro that BMP-2 mediated mineralization was 
significantly increased when heparin was incorporated in the collagen matrix, while the 
delivery of pre-complexed BMP-2 and heparin in the collagen matrix had less 
mineralization.  The observations of bone repair in vivo resulted in different conclusions.  
First, the in vitro and in vivo assay systems have different experimental designs, and 
therefore may result in differing conclusions.  Also, the differences observed may have 
been caused by the many additional factors present in vivo that are not in the controlled in 
vitro environment, such as inflammatory responses, endogenous growth factors and 
antagonists [39, 64].  This complex in vivo environment often compounds the interactions 
between growth factors, receptors, and matrix components such as heparin.  For example, 
previous work has shown that activation of macrophages causes a decrease in local pH to 
below 5 [198].  This decrease in pH causes a significant decrease in BMP-2 binding and 
results in rapid clearance of the growth factor, as shown in work performed by Friess, et 
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al. [15].  In vivo the pre-complexed BMP-2/heparin group was the only condition to 
restore properties, indicating that stabilizing the BMP-2 molecule provides a significant 
advantage in the in vivo environment. 
The release kinetics of growth factors are also drastically different in vivo, as 
shown by Kempen, et al. [22].  They demonstrated that their scaffolds had a larger burst 
release and overall faster release of BMP-2 in vivo compared to similar release 
experiments in vitro [22].  Other research has shown that release properties are very 
dependent on the conditions in the immediate environment (i.e. pH, chemical 
composition, temperature) [149].  Therefore the release of BMP-2 in vivo may be very 
distinct from in vitro release kinetics, as well as varying kinetics at different sites in vivo, 
thereby having a different effect.   
Growth factors delivered bound to the matrix results in no circulating signal 
reaching the surrounding cells that could initiate migration, proliferation, and 
differentiation into the defect site.  Rizzi, et al. demonstrated that physical linkage of 
BMP-2 to a PEG matrix resulted in suboptimal bone formation in a rat calvarial defect 
model [199].  Matrix-bound growth factors can only transmit signals to nearby cells, 
whereas soluble growth factors are able to freely diffuse and act on the surrounding cells 
via paracrine signaling [174].  On the other hand, if the growth factor diffuses from the 
defect too rapidly, there will be insufficient sustainment of the osteoinductive signal to 
induce a significant biological response.  This rapid diffusion has been observed in the 
current clinical treatments, which has been overcome with large, unsafe doses.  These 
conflicting conditions introduce very significant challenges when designing an optimal 
spatiotemporal growth factor delivery system [100, 108].  Lutolf, et al. developed an 
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inducible system that enabled either rapid solubilization of BMP-2 or using an MMP-
sensitive PEG gel system [200].  They demonstrated that the lack of a soluble BMP-2 
signal resulted in less bone formation in a cranial defect and the MMP-sensitive implants 
released BMP-2 in relation to cell invasion into the gel resulting in higher amounts of 
bone formation [200]. 
Delivery of pre-complexed BMP-2/heparin in the collagen matrix presented in 
this work performed the best in vivo. The heparin helped protect the diffuse BMP-2 
molecule from degradation, thereby maintaining the BMP-2 structure and subsequent 
bioactivity in the surrounding tissue [96, 117].  Design considerations for BMP-2 
delivery systems not only need to address the temporal requirements, but also must 
ensure that the released BMP-2 remains biologically active [201].  The pre-complexing 
of BMP-2 and heparin resulted in significantly greater bone formation than both non-
BMP-2 control groups, and was the only group not significantly different from intact 
bone properties.  While this pre-complexed group was not significantly greater than the 
other BMP-2 groups, the delivery of BMP-2 in collagen and collagen/heparin matrices 
resulted in significantly lower mechanical properties than intact bone.  These results 
indicate that further design of a BMP-2/heparin co-delivery system may prove to be a 
potential graft substitute therapy. 
5.6 Conclusions 
The work presented in this Chapter focused on evaluating the affinity-based 
BMP-2 delivery system previously developed in Specific Aim II (Chapter 4) in a 
challenging in vivo bone repair model.  We observed that the delivery of pre-bound 
BMP-2 and heparin in a collagen matrix induced bone regeneration with mechanical 
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properties closest to those of native bone, while delivery of BMP-2 in collagen or 
collagen/heparin matrices had similar volumes of regenerated mineralized tissue but had 
significantly lower mechanical strengths than intact bone.  We observed that the 
heparinized delivery system performed differently in vitro and in vivo, suggesting that in 
vivo experiments remain necessary to fully evaluate potential tissue engineering 
therapies.  The results observed in this chapter indicate that the co-delivery of both BMP-




CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Summary 
Tissue-engineered products that utilize growth factors to induce tissue 
regeneration and repair have demonstrated significant potential because of the highly 
specific activity of growth factors to induce cell differentiation, migration, proliferation, 
and matrix production.  Such tissue engineering approaches involve the delivery of the 
growth factors within a carrier biomaterial.  These carriers are included to provide a 
structure for tissue regeneration to occur on, as well as retain the growth factor at the 
implant site.  However, current carriers are limited by their poor affinity for growth 
factors leading to rapid diffusion from the construct.  Upon release from the carrier, 
protein therapies are further limited by poor protein stability.  These limiting factors 
result in the use of high doses, and frequent injections.  To address these limitations, 
delivery systems that are able to optimally control the rate and location of growth factor 
release are being investigated.  
The goal of this work was to develop and evaluate the efficacy of BMP-2 delivery 
systems to improve bone regeneration.  We examined two approaches for delivery of 
BMP-2 in this work.  First, we determined the efficacy of a self-assembling lipid 
microtube system for the sustained delivery of BMP-2 (Specific Aim I, Chapter 3).  We 
determined that sustained delivery of BMP-2 from the lipid microtube system was able to 
enhance osteogenic differentiation compared to control microtubes, however did not 
demonstrate a significant advantage over a bolus BMP-2 dose in vitro.  Second, we 
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examined the use of an affinity-based system to sequester BMP-2 at the implant site and 
retain bioactivity by incorporating heparin within a collagen matrix (Specific Aim II, 
Chapter 4).  Incorporation of heparin in the collagen matrix improved BMP-2 retention 
and bioactivity, thus enhancing cell-mediated mineralization in vitro.  Lastly, the affinity-
based BMP-2 delivery system was evaluated in a challenging in vivo bone repair model 
(Specific Aim III, Chapter 5).  Delivery of pre-complexed BMP-2 and heparin in a 
collagen matrix induced bone regeneration with mechanical properties not significantly 
different from those of intact bone, whereas delivery of BMP-2 in collagen or 
collagen/heparin matrices had significantly lower mechanical properties than intact bone. 
6.2 Sustained delivery of BMP-2 in lipid microtubes 
In Specific Aim I we characterized the sustained release of BMP-2 from lipid 
microtubes and showed that the BMP-2 released from the microtubes remained 
biologically active.  Therefore, we hypothesized that the lipid microtubes would improve 
BMP-2 mediated mineralization compared to a bolus dose and be a potential BMP-2 
delivery system for bone tissue engineering.   
Sustained delivery of BMP-2 from the microtubes demonstrated increased 
osteogenic differentiation compared to control microtubes, indicating the release of 
bioactive BMP-2.  However, when compared to a bolus BMP-2 dose, this sustained 
release approach did not provide a significant advantage for osteogenic differentiation 
compared in vitro.  Other studies have shown that the kinetics of BMP-2 exposure is a 
major factor for mineralization [16, 157-159].  Some have also hypothesized that a 
system with a biphasic release profile consisting of a burst release to recruit 
osteoprogenitor cells, followed by sustained release of growth factor to induce 
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differentiation of those recruited cells will be the most effective therapy [16, 100, 158]. 
Bostrom, et al. showed that there is a large increase in endogenous BMP and BMP 
receptor expression in the fracture callus immediately after fracture, inducing new woven 
bone formation within 1-2 weeks [33].  As the woven bone is remodeled into lamellar 
bone, the expression of BMPs decreases [33].  Endogenous expression can be stimulated 
by BMPs secreted by other cells or by exogenously added BMPs [202].  Therefore, 
exogenous addition of a higher concentration of BMP-2 followed by a lower, steady 
release of BMP-2 dose may enhance the native BMP expression profile, thereby 
potentiating bone repair.  Future studies may possibly focus on combining the sustained 
release of BMP-2 from microtubes with an initial burst release component to determine a 
more efficacious release for mineralization.  This could be achieved by delivering the 
BMP-loaded microtubes in a hydrogel carrier with unencapsulated BMP-2 suspended in 
the hydrogel.  The two modes of BMP-2 delivery within the same system may provide a 
biphasic release profile. 
The in vitro assays used in this thesis to examine the microtube performance were 
limited to two-dimensional cell assays.  It has been demonstrated previously that cells 
respond very differently in two-dimensional and three-dimensional culture systems [203].  
Since tissue engineering mainly requires three-dimensional constructs, potential therapies 
need to be validated in those conditions.   We considered experimental designs to test this 
microtube delivery system in a 3D cell assay, and examined methods to deliver these 
microtubes in a 3D construct.  Due to the small size of the microtubes, a hydrogel with 
low porosity is necessary for suspension in a 3D structure. Therefore, the microtubes 
were suspended in an RGD-alginate gel to achieve the necessary 3D structure for in vivo 
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implantation.  We chose the RGD-alginate because it has been used previously for bone 
defect repair with BMP-2 [82, 189, 190].  However, cell culture within these gels is 
difficult and often results in significant cell death due to a lack of nutrient transport 
through the small pores of the hydrogel [204].  Previous work has examined the 
bioactivity of growth factors in delivered in 3D hydrogel systems by co-culturing cells 
with the delivery system suspended in transwells [22, 205].  However, these assays only 
examine the response of 2D cell cultures to the soluble released BMP-2, and do not 
directly assess cell responses in a 3D system.  Therefore, future work can focus on 
developing a more effective 3D in vitro assay system.   
The in vitro responses to the bolus BMP-2 and sustained release of BMP-2 may 
not directly correspond to potential in vivo results.  We examined the in vivo response to 
the lipid microtube delivery system using the RGD-alginate system to suspend in 3D 
PCL scaffolds (data not included in this thesis).  We observed that concentrations in 
excess of 5 mg/ml lipid microtubes in the alginate resulted in poor gel formation.  This 
constraint in microtube concentration was a limiting factor when attempting to load 
physiological doses of BMP-2 into the microtube-alginate system.  In order to obtain a 
high enough concentration of BMP-2 within the low concentration of microtubes, the 
microtubes would need to be incubated in very highly concentrated BMP-2 solutions 
(greater than 300 µg/ml) for the loading process.  The loading concentration in addition 
to the limit of microtubes in the alginate solution leads to a restriction on how much 
BMP-2 can be loaded into the microtube-alginate system, which we determined to be 
approximately 0.5 µg/construct, or 5 µg/ml.  We then examined the in vivo subcutaneous 
delivery of 0.5 µg BMP-2 in the microtubes suspended in the alginate gel and saw that 
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there was not a significant amount of mineralization in the constructs after 8 weeks.  The 
same dose of BMP-2 delivered in the alginate gel without the microtubes also did not 
exhibit a significant amount of mineral formation, indicating that this dose was 
insufficient for in vivo applications.  Other studies using similar in vivo ectopic models 
have demonstrated that doses of at least 1-2 µg BMP-2/construct were required to induce 
mineralization [186, 206, 207].  
BMP-2 is generally known to require much higher doses than other growth factors 
and cytokines [95].    Therefore, a higher concentration of BMP-2 in the microtubes may 
have proved to be more advantageous than the bolus dose.  However, a major concern 
with current clinical treatments is the high dose and cost of BMP-2 [103].  Thus 
increasing the dose in the microtube system will result in similar concerns.  Although this 
microtube sustained delivery approach for BMP-2 did not provide a significant advantage 
over a bolus dose, there may be use for this system in bone tissue engineering by 
incorporating other osteogenic factors.  This includes growth factors such as bFGF, EGF, 
VEGF, or TGF-ß, which have been shown to have an effect on bone healing at lower 
doses [39, 51, 97, 110, 208].  TGF-ß has previously been delivered in the lipid microtube 
system at a dose of 20-25 ng for wound healing applications, therefore this delivery 
approach for TGF-ß may also be beneficial for bone tissue engineering [82, 137]. 
6.3 Delivery of BMP-2 in a collagen/heparin matrix 
The work presented for Specific Aims II and III addressed the hypothesis that the 
collagen/heparin matrix would improve BMP-2 retention and bioactivity.  We showed 
that BMP-2 quickly releases from collagen matrices, and diffuses much slower from 
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collagen/heparin matrices in vitro.  In addition, BMP-2 delivered in collagen/heparin 
matrices improved BMP-2 mediated differentiation in vitro. 
There are multiple possible mechanisms of BMP-2 release from an affinity-based 
system including: solubility of the carrier-bound molecule (i.e. heparin), solubility of the 
growth factor, and degradation of the carrier [111, 114, 201].  However, the mode of 
release remains unclear from the in vitro release kinetics and confocal analyses presented 
in Chapter 4.  Previous work has used mathematical models to understand the release of 
growth factors from heparinized delivery systems [111, 114].  This model demonstrated 
that much of the heparin is released through matrix degradation, and not through passive 
diffusion of the molecules [111, 114].  They also showed that growth factor release rate 
was largely dependent on the affinity to heparin, with release rate increasing as the 
heparin affinity was decreased [111].  However, these studies assumed that the 
association and dissociation rate constants for growth factors with heparin were the same 
regardless of pre-complexation of heparin with the matrix component, and likewise the 
heparin binds to the matrix with the same kinetics regardless of pre-complexation with 
BMP-2.  These assumptions simplify the mathematical model to make solutions possible, 
however are not realistic and may result in inaccurate results.  
A possible approach to determine how the BMP-2 and heparin are released from 
this system is to fluorescently-label both the BMP-2 and heparin to observe the co-
localization of the two fluorescently labeled molecules.  In preliminary work, we labeled 
heparin with Alexa Fluor 488 using a protocol previously described by Osmond, et al. 
[29].  However, this fluorescent probe has similar excitation and emission wavelengths to 
the FITC probe used in Chapter 4 to observe BMP-2 in the matrices, therefore these two 
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fluorescent probes cannot be observed simultaneously to determine the co-localization of 
BMP-2 and heparin.  To resolve this, another probe may be used for either BMP-2 or 
heparin at different excitation and emission wavelengths to concurrently observe the two 
molecules.  However, an important consideration when determining which fluorescent 
probes to use is the auto-fluorescent properties of collagen at certain wavelengths.  
Therefore, both probes will need to be at different wavelengths from the auto-fluorescent 
wavelength of collagen (excitation 470-490 nm, emission 550 nm) [209].   
We observed that heparin concentration in the collagen matrix had an effect on 
BMP-2 content using the confocal microscopy method.  Another consideration for this 
delivery system is the collagen concentration.  Higher concentrations of collagen may 
provide lower matrix porosity and slower degradation, resulting in slower diffusion of 
molecules from the matrix [198].  The spatial dimensions of BMP-2 are much smaller 
than the pores of the collagen matrix, therefore diffusion is not inhibited or delayed by 
the matrix dimensions and is mainly dependent on the interactions of BMP-2 with the 
matrix components.  Work performed by Friess, et al. demonstrated that higher 
concentrations of collagen resulted in higher BMP-2 retention and improved 
mineralization [15]. 
6.4 In vivo evaluation of collagen/heparin delivery system 
In Specific Aim III we evaluated the collagen/heparin delivery system in a 
challenging in vivo model.  We demonstrated that although BMP-2 delivered in the 
collagen/heparin matrix outperformed all other groups in the in vitro assays, the results in 
vivo were not as promising. Interestingly, delivery of pre-complexed BMP-2/heparin in 
the collagen matrix performed the best in our in vivo model.   
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The different conclusions from in vitro and in vivo experiments may have been 
caused by the differing experimental design and conditions.  First, the in vitro assays had 
cells directly seeded on the scaffolds; therefore the BMP-2 signal did not have to diffuse 
to the surrounding environment to induce cellular activity. In vivo, the growth factor 
delivered in the heparinized results in less diffusible signal to the surrounding cells that 
could potentiate migration, proliferation, and differentiation into the defect site.  Kim et 
al., showed a similar effect in vivo where BMP-2 delivered to an ecoptic site via heparin-
conjugated PLGA nanoparticles had a significantly greater effect on mineralization with 
simultaneous delivery of undifferentiated MSCs [115].  On the other hand, if the growth 
factor too readily diffuses out of the construct, there will be inadequate sustainment of the 
osteoinductive signal to achieve a significant biological response in the cells that migrate 
to the defect site, unless a large dose is delivered.  Hubbell, et al. has investigated 
methods of delivering growth factors within matrices that prevent the diffusion of the 
growth factor but permits its release upon local cell-mediated activation of matrix-
degrading enzymes [114, 199, 210].  In vitro confocal analysis performed in Specific 
Aim II demonstrated that the BMP-2/heparin in the collagen matrix did not have as high 
levels of retention as BMP-2 did in the collagen/heparin matrix, but had better retention 
than BMP-2 in the collagen matrix.   This indicates that in vivo, the BMP-2/heparin 
complex was able to diffuse out of the collagen matrix, but not so quickly as to remove 
the osteoinductive signal immediately after implantation.   
There may have also been the added benefit that the pre-complexed BMP-
2/heparin was released from the collagen matrix as a complex, which helped to protect 
the diffuse BMP-2 molecule from degradation, thereby prolonging and enhancing the 
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BMP-2 activity in vivo.  Whereas, the BMP-2 delivered in the collagen/heparin matrix 
could have been released as BMP-2 only or as a complex with BMP-2, in which case the 
free BMP-2 will be quickly degraded.  However, these possibilities were unclear from in 
vitro release kinetics and confocal analyses.  Future studies could focus on determining 
the release kinetics for this delivery system in vivo.  Characterization of in vivo growth 
factor release kinetics has previously been achieved using radioiodinated BMP-2 [15, 18, 
128, 158].  However, the short half-life of these radiolabels may be a limitation for longer 
term in vivo studies, such as the segmental defect model.  These radiolabels also involve 
exposing animals to ionizing radiation, which may have a negative effect on healing 
processes [211].  Other research has focused on developing noninvasive optical imaging 
techniques to track release of growth factors in vivo [212, 213].  A novel method was 
developed by Diagaradjane, et al. to track EGF in vivo using near-infrared quantum dots 
(QD) [213].  This group conjugated amine-functionalized QD to the EGF and performed 
in vivo optical imaging using an IVIS imaging system (Caliper Life Sciences, Mountain 
View, CA, USA) [213].  Analysis of the BMP-2 release kinetics in vivo may help clarify 
the results seen in Chapter 5 and provide a more complete assessment of this tissue 
engineering approach. 
Heparin has been shown to have a significant effect on BMP-2 stability, activity, 
and inhibition [96, 117].  Therefore, the pre-complexed BMP-2/heparin group in vivo 
may have had the advantage of enhancing the BMP-2 binding to its receptor and 
protecting it from degradation thereby increasing its osteoinductive activity.  This benefit 
of co-delivering BMP-2 and heparin may be beneficial in other carriers that have shown 
success in bone repair applications, such as the RGD-alginate hydrogel carrier previously 
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used by Kolambkar, et al. [195].  Another possible application of this co-delivery 
approach in order to stabilize and improve BMP-2 activity, is to use synthetic heparin-
like molecules that don’t have the same side effects of heparin [214].  Antibody-binding 
systems have also been used to retain and stabilize growth factors at the defect site [113].   
 Collagen concentration is an important design parameter that can improve the 
performance of BMP-2 delivery and therefore should also be examined in vivo [5].  As 
previously stated, the in vivo environment is very different from the controlled in vitro 
environment.  Therefore a higher concentration of collagen may be necessary for in vivo 
applications to ensure matrix integrity upon implantation and prevent immediate 
solubilization of matrix molecules.  The structural integrity of collagen sponges have 
been a concern previously, without a viable solution thus far [11].  The basis of this 
delivery system depends on the integrity of the matrix over time.  The heparinized matrix 
may have had more of an effect if the matrix was degraded slower in vivo, reducing the 
solubilization of heparin.  Research done by Uludag, et al. demonstrated previously that 
different preparations of collagen sponges changed the in vivo BMP-2 release kinetics 
[18].  
This delivery system is not limited to applications for BMP-2.  Enhanced growth 
factor activity is possible with use of any heparin-binding growth factor, such as VEGF 
and bFGF [26, 175].  However, characterization of the co-delivery with heparin specific 
to the growth factor of interest will be necessary due to the differing affinities for heparin 
among growth factors.  For example, VEGF is mainly soluble and only binds heparin 
with low affinity, while BMP-2 binds heparin with high affinity [60].  This could result in 
different potential activity of VEGF with the heparin system than with BMP-2. 
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Previous work has attempted to correlate mechanical properties to bone volume in 
order to develop a method of estimating stiffness and maximum torque from in vivo or in 
vitro micro-CT scans and found that strong correlations with max torque depended on 
meeting a certain minimum bone volume [190].  Other work performed by Reynolds, et 
al. developed a method to correlate micro-CT measurements with biomechanical 
properties in order to assess the performance of autografts and allografts [74, 77].  The 
work in this thesis was able to demonstrate correlations between mineral matrix 
characteristics measured with the micro-CT and mechanical properties.  Although the 
overall bone volumes and connectivity densities were not largely different between 
groups, these correlations varied with each treatment, indicating differences in matrix 
organization, which contributes to the mechanical properties.  Future work could focus on 
examining the relationships between the matrix organization and material properties 
during fracture healing in order to assess remodeling of regenerated tissue into mature 
bone.  Histological stains have been used previously to assess matrix composition and 
organization to determine mature bone formation [61, 62].  FT-IR imaging and 
spectroscopy have also been utilized to analyze matrix composition [41].  However, these 
techniques are semi-quantitative, destructive, and do not allow for the direct comparisons 
of bone matrix organization to biomechanical properties within the same samples.  
Developing a non-invasive quantitative CT method to assess fracture healing may prove 
to be clinically beneficial to identify patients with poor restoration of mechanical 
properties and are at risk for re-fracture. 
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6.5 Conclusions 
Tissue engineering approaches involving growth factors have demonstrated 
significant potential because of their highly specific activity and ability to induce a 
variety of cell functions that are vital to tissue repair.  The work in this thesis was 
performed to address some of the limitations currently preventing optimal performance of 
protein therapies, including stability, duration of exposure, and localization at the 
treatment site.  We evaluated two approaches for the delivery of BMP-2.  First, we 
examined the sustained release of BMP-2 from a lipid microtube system and 
demonstrated that this delivery approach was not significantly advantageous compared to 
a bolus dose of BMP-2 in vitro.  Next, we developed and evaluated an affinity-based 
BMP-2 delivery system employing the binding affinity of heparin.  We demonstrated that 
this heparinized collagen system improved BMP-2 retention and bioactivity in vitro; 
therefore we decided to validate this system in a small animal model.  The in vivo results 
demonstrated a benefit when BMP-2 and heparin were pre-complexed and delivered in 
the collagen matrix, resulting in bone formation with mechanical properties not 
significantly different from those of intact bone.    These results indicate that co-delivery 
of BMP-2 and heparin potentiates bone repair.  Therefore, further consideration of 
systems with co-delivery of BMP-2 and heparin may result in a potential graft substitute 
treatment for clinically challenging bone defects. 
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APPENDIX A 
FORMATION OF LIPID MICROTUBES 
Purpose: 
To form microtubes from DC8,9PC lipid for growth factor sustained delivery 
experiments.  Procedure adapted from Meilander, et al. [120]. 
Materials: 
1) 1,2-bis(tricosa-10,12-diyonyl)-sn-3-phosphocholine (powder, DC8,9PC, Avanti Polar 
Lipids, Alabaster, AL, USA) 
2) Trehalose cryoprotectant (Sigma, St. Louis, MO, USA) 
3) 100% ethanol 
4) sterile deionized water 
5) 15ml conical tubes 
6)  Microprocessor-controlled refrigerated water bath (Isotemp Refrigerated Circulator, 
Fisher Scientific, Waltham, MA, USA) 
Procedure: 
1) Preheat water bath to 55°C 
2) In separate 15 ml conical tubes, warm 7 ml of 100% ethanol and 3 ml sterile water to 
55°C 
3) Dissolve 10 mg lipid in the 7 ml of warm ethanol 
4) Slowly add the water to the lipid/ethanol solution and discard the empty water tube 
5) Place the lipid solution in the warm water bath 
6) Use the following program to slowly cool the lipid solution in the water bath (total 
running time of 48 hours) 
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Table A.1 Cooling program for lipid microtube formation 
Step Start Temp (°C) End Temp (°C) Interval time (hours) 
1 55 53 5 
2 53 23 20 
3 23 21 6 
4 21 33 2 
5 33 32 2 
6 32 25 6 
7* 25 20 7 
*Program can be ended at any time during the last 7 hours (step 7) 
7) Remove the 15 ml conical containing the lipid solution from the water bath 
8) Incubate the lipid solution for two weeks at room temperature protected from light to 
allow the microtubes to completely form 
9) Add 50mM trehalose (189mg/10ml) to the lipid solution and mix gently.  Incubate 
overnight at room temperature 
10) Centrifuge the lipid microtubes for 10 min at 1500g, remove the supernatant 
11) Resuspend the microtubes in 0.5 ml sterile water 
12) Lyophilize the microtubes for several hours until dry 
13) Load the microtubes by rehydrating the dried microtubes in the protein solution of 
interest (40µl per mg of lipid) and incubate overnight at 8°C. 
14) Centrifuge the protein-loaded lipid microtubes for 10 min at 1500g and remove the 
supernatant 
15) Wash the microtubes with 0.5 ml sterile water twice, centrifuging and removing the 
supernatant after each wash 
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APPENDIX B 
SELECTION OF MEDIA COMPONENTS FOR BMP-2 MEDIATED 
DIFFERENTIATION IN hMSCs 
Purpose: 
To determine the components of the cell culture media supplements in order to 
observe BMP-2 mediated differentiation of hMSCs. This includes determining the effect 
of dexamethasone and thyroxine on BMP-2 mediated differentiation.   
Materials and Methods: 
 Cells were expanded and differentiated as described in Chapter 3.  Media 
supplements are listed in Table B.1.  RNA was isolated from cell layers and analyzed 
with quantitative real-time RT-PCR as described in Chapter 3.   
Table B.1 Experimental groups to determine media supplements for analysis of BMP-2 
mediated differentiation 
Groups Dex (nM) / 
Thyroxine (ng/ml) 
BMP-2 (ng/ml) 
1 -- -- 
2 -- 100 
3 1 / 50 -- 
4 1 / 50 100 
 
 Data are presented is the mean ± standard error of the mean (SEM).  Statistical 
comparisons using Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA) 
were based on an ANOVA and Tukey’s post hoc analysis for pairwise comparison of 




 The addition of dexamethasone & thyroxine seemed to have a saturation effect on 
the cells, causing the groups without BMP-2 to express high levels of osteogenic 
genes(Figure B.1).  This resulted in no significant differences occurring between groups 
with or without BMP-2 when dexamethasone and thyroxine were included in the 
differentiation media. However, when dexamethasone and thyroxine were excluded from 
the media there were significant differences in gene expression between groups with or 
without BMP-2.  
Conclusions: 
 Reducing the levels of media supplements that may encourage osteogenic 
differentiation allows for clearer evaluation of BMP-2 mediated differentiation.  BMP-2 
alone has been shown to have a greater effect on differentiation over dexamethasone 
[125].  In this experiment the addition of dexamethasone and thyroxine appeared to mask 
the differentiation effects of BMP-2. 
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Figure B.1 Effect of dexamethasone and thyroxine on BMP-2 mediated osteogenic gene 
expression was assessed by real time RT-PCR analysis of osteoblastic markers including 
alkaline phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN), and Runx2. ★ 
p<0.05 and ★★ p<0.01 compared to (-) BMP-2.   
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APPENDIX C 
BMP-2 DOSE RESPONSE OF OSTEOGENIC DIFFERENTIATION 
IN hMSCs 
Purpose: 
The purpose of this study was to determine the effects of dose and kinetics of 
BMP-2 exposure on osteogenic differentiation of hMSCs in vitro.  First, determine the 
minimum dose of BMP-2 to induce osteogenic differentiation of hMSCs in vitro.  
Second, determine the effect of different durations of BMP-2 exposure on hMSC 
differentiation in vitro. 
Materials and Methods: 
 Cells were expanded and differentiated as described in Chapter 3. RNA was 
isolated from cell layers and analyzed with quantitative real-time RT-PCR as described in 
Chapter 3. 
Results: 
In order to understand the differences seen between bolus delivery of BMP-2 and 
sustained release of BMP-2 in Chapter 3, the dose of BMP-2 was varied in cell culture 
media and the response was measured using RT-PCR. The dose requirement was 
examined by exposing hMSCs to different concentrations of BMP-2 for the entire 
duration of the 28 days in culture.  The data indicate that osteogenic differentiation of 
hMSCs requires delivery of a minimum dose of 25 ng/ml BMP-2 (Figure C.1).  The 
lowest dose (1 ng/ml) only increased Runx2 expression after 28 days, however remained 
lower than the other BMP-2 groups.  
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Figure C.1 BMP-2 dose response of osteogenic gene expression assessed by real time 
RT-PCR analysis of osteoblastic markers bone sialoprotein and Runx2.  p<0.05: ★ 
compared to control,   compared to BMP-2 (1 ng/ml),  compared to all groups. 
Conclusions: 
In this study we showed that a dose greater than 25 ng/ml is required to induce a 
significant osteogenic response in hMSCs in vitro.  Other in vitro assays have 
demonstrated that BMP-2 only induces a significant cell response at doses above 10-25 
ng/ml [91, 215, 216].  The lipid microtube system presented in Chapter 3 releases in 
incremental doses smaller than 25 ng/ml.  Therefore, the sustained release of low dose 
BMP-2 may not be beneficial for bone tissue engineering.  Previous work has shown that 
BMP-2 activity in vivo may be more beneficial with a larger initial dose rather than small, 
continuous doses [16, 100].   
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APPENDIX D 
OPTIMIZATION OF CONFOCAL MICROSCOPE PARAMETERS 
FOR THE QUANTIFICATION OF FITC-LABELED BMP-2 
Purpose: 
 Tissue engineering requires careful and deliberate selections of materials and 
biological agents to induce the desired effect.  This choice and optimization of materials 
highly depends on sensitive and repeatable quantitative methods to measure the 
performance.  Imaging techniques have a tremendous potential to help develop and 
improve tissue engineering strategies.  Therefore, it is imperative to develop accurate and 
rapid imaging methods to understand the overall performance of tissue engineering 
approaches.  Confocal miscrocopy and other characterization techniques have been used 
previously to determine protein content on two-dimensional, fixed samples [185, 217].  
However, most tissue engineering constructs are three-dimensional and will require 
assessment in all spatial dimensions.  This study focused on developing a simple and 
rapid protocol using confocal laser scanning microscopy (CLSM) for quantifying and 
analyzing protein content in 3D constructs. 
Procedure: 
Table D.1 Confocal microscope image capture parameters 
Scan Mode Plane, multi track, 8 bit 
Stack Size 512 x 512, 912.4 µm x 921.4 µm 
Pixel Time 1.6 µs 
Objective A-Plan 10x/0.25 PH1 
Wavelength 488 nm 




 FITC-labeled BMP-2 was placed on microscope slides with glass coverslips (size 
1) at increasing concentrations and imaged on a CLSM.  The images were analyzed using 
the LSM 510 image software (Zeiss, Inc., Thornwood, NY). The first method used to 
determine levels of background signal at increasing concentrations of fluorescent protein, 
was to quantify the total fluorescent area at different image threshold levels (Figure 
D.2A).  At threshold levels below 30 the total area was nearly equivalent to the total area 
of the image slice (~1 mm2, areas corresponding to thresholds below 20 were excluded 
from Figure D.2A).  This indicates that the fluorescent signal intensity is well above a 
threshold of 30. 
Another method of determining background levels in CLSM images is to quantify 
the coefficient of variance (CV), also known as the signal-to-noise ratio (Figure D.3).  
This value is defined as the ratio of the standard deviation (σ) to the mean fluorescent 
intensity (µ) of a population of pixels [218].  The CV is only defined for non-zero means 
and generally only for populations with positive values.  In general, a lower CV (<1) 
corresponds to a system with low background signals and good resolution.  Therefore, an 
image threshold level that results in lower CV values is optimal. 
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Figure D.1  Confocal microscope image of FITC-labeled BMP-2 standards.  Scale bar = 
100µm 
 
Figure D.2  Quantification of FITC-labeled BMP-2 standards using confocal microscopy 
(A) Fluorescent area (µm2) at different fluorescent thresholds (values at thresholds less 
than 20 were excluded from the graph); (B) Quantification of the coefficient of variance 
(σ/µ) at different fluorescent thresholds; (n=3). 
A threshold level of 50 was chosen to reduce the overall amount of background 
signal, while also ensuring no actual fluorescent signal was excluded.  The fluorescent 
intensity area at threshold 50 was linearly correlated to the concentration of FITC-labeled 
protein (R2 = 0.9604, Figure D.3).  Lower threshold values resulted in weaker 
correlations (i.e. at threshold 10, R2 = 0.2592).  A line was fit to the correlating 
fluorescent intensity and FITC concentration data to be used in future studies to 
approximate the amount of BMP-2 in 3D scaffolds from CLSM images. 
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Figure D.3 Standard curve correlating FITC-labeled BMP-2 concentration (µg/ml) to 
fluorescent area (µm2) at a threshold of 50 (n=3). 
Conclusions: 
 The purpose of this experiment was to develop a protocol for the quantification of 
fluorescent signals from FITC-labeled BMP-2 using confocal laser scanning microscopy 
[219].  It was determined that a threshold value of 50 reduced the amount of background 
noise, while also not excluding the actual FITC signals.  Lower threshold levels resulted 
in large amounts of background signal included in the calculations, and higher threshold 
levels resulted in much of the FITC-labeled protein excluded from the calculations.  
These methods utilize tools commonly available on confocal microscopes and can be 
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